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Immune repertoire sequencing (IR-Seq) rapidly emerged with the advent of high-
throughput sequencing as a means of characterizing the adaptive immune system. Early 
generations of IR-Seq were plagued by sequencing errors and low diversity coverage. We 
developed Molecular Identifier Clustering-based IR-Seq (MIDCIRS) to quantitatively 
and comprehensively measure the immune repertoire from a small amount of blood. We 
used naive B cells to formulate a general framework for IR-Seq experimental validation 
and quality control and showed that MIDCIRS can be applied to as few as 1,000 naive B 
cells with excellent diversity coverage.  
Using MIDCIRS, we studied the antibody repertoire response to acute malaria 
infection in young children. We found that the infant antibody repertoire is surprisingly 
competent at introducing somatic hypermutations (SHM) and diversifying B cell clonal 
lineages in response to malaria infection. Detailed analysis of memory B cell-containing 
lineages in malaria-experienced toddlers revealed that memory B cells further mutate 
upon malaria rechallenge. IgM-expressing memory B cells largely retain IgM expression 
upon rechallenge, but a subset class switch to IgG and IgA.  
 viii 
Accurate antibody repertoire analysis requires not only accurate sequencing data, 
but also correct reference germline allele sequences. Mismatches between the reference 
sequence and an individual’s true germline sequence would be mistakenly counted as 
SHMs, inflating the SHM load and skewing the repertoire analysis. We developed a 
simple yet effect method for predicting novel germline allele sequences from antibody 
repertoire data and validating them via targeted sequencing of non-rearranged genomic 
DNA. 
HIV infection has a profound impact on the CD4+ T cell compartment, which can 
have a devastating effect on the adaptive immune system as a whole. Paradoxically, 
while peripheral CD4+ T cell counts drop with disease severity, TFH cells show an inverse 
relationship. We found that these expanded TFH cells exhibit a functionally restricted 
phenotype, which could contribute to ineffective antibody responses both to HIV and 
unrelated vaccines. Using MIDCIRS, we found that these expanded TFH cells are 
enriched with HIV-specific sequences and show signs of antigen-driven convergent 
evolution, suggesting that HIV-specific T cells are selected and recruited into the TFH 
compartment during infection. 
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Chapter 1: Background 
1.1 ADAPTIVE IMMUNITY 
The immune system is necessarily complex to combat the universe of possible 
pathogens that an individual can be exposed to throughout his or her lifetime. The bulk of 
this complexity resides in the adaptive branch – the component that recognizes and 
responds to specific antigens. As its name implies, the adaptive immune system evolves 
to more effectively subdue foreign agents that it has previously encountered. Achieving 
this is no small task, and the underlying biology is a subject of great scientific interest, 
particularly to the medical field. Vaccines have long been used with great success to elicit 
an adaptive immune response in place of an actual infection to confer protection against 
diseases. More recently, therapeutic antibodies and engineered T cells have emerged as 
exciting areas of research towards the treatment of a wide range of diseases, including 
HIV1, pertussis2, Ebola3, and various types of cancers4, 5, 6, 7.  
The adaptive immune system is composed of B and T lymphocytes. These cells 
differentiate from a common lymphoid progenitor that stems from hematopoietic stem 
cells in the bone marrow. Pre-B cells continue to mature in the bone marrow, while 
immature T cells migrate to the thymus to finish developing. Mature B cells express B 
cell receptors (BCR) that determine their antigen-specificity. Likewise, mature T cells 
express T cell receptors (TCR). BCRs interact with 3-dimensional epitopes, such as viral 
or bacterial surface proteins or secreted toxins. On the other hand, TCR specificities are 
restricted to linear peptide sequences that are presented by major histocompatibility 
complex (MHC) proteins on the surface of host cells. Activated B cells can secrete their 
BCRs, interchangeably termed antibodies or immunoglobulin (Ig), to neutralize their 
target antigens systemically and contribute to humoral immunity. T cells depend on cell-
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to-cell (TCR-MHC) contacts and contribute to cell-mediated immunity. The collection of 
BCRs within an individual is commonly referred to as the BCR or antibody repertoire, 
and the collection of TCRs is commonly referred to as the TCR repertoire.  
Lymphocytes are one of the few types of somatic cells that induce irreversible 
changes to their genomic DNA on the sequence level.  This process, coined V(D)J 
recombination, occurs during the maturation of B and T cells from their hematopoietic 
stem cell precursors, resulting in newly formed, naïve B and T cells with unique BCRs 
and TCRs, respectively.  In the case of the BCR heavy chain, individuals have 42-51 
distinct functional or open reading frame V genes, 27 D genes, and 6 J genes within their 
haploid germline genomic DNA8.  During V(D)J recombination, one V, one D, and one J 
allele are stitched together (recombined), with the DNA between them being permanently 
excised.  Random nucleotides can be added and/or removed at the junctions. The region 
surround the D gene is termed the Complementary Determining Region 3 (CDR3) 
because this short stretch of around 60 base pairs (bp) accounts for a major portion of the 
diversity and is located at the antigen binding sites.  BCRs are made up of two separate 
polypeptides, the heavy chain and light chain, which are post-translationally joined via 
covalent di-sulfide bonds. A dimer of two such complexes forms a functional BCR.  Both 
the heavy and light chains recombine independently in a similar manner; however, the 
light chain lacks the D gene. In humans, the light chain comes in two variants – kappa 
and lambda – which each have their own collection of V and J genes.  Similarly, TCRs 
are a heterodimer of an alpha and beta chain or gamma and delta chain.  As these changes 
occur on the genomic DNA level, they are passed on to the progeny of the mature 
lymphocytes, leading to clonal families with identical antigen receptors.  Stimulated B 
cells, but not T cells, can further undergo somatic hypermutation (SHM) – a process 
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which introduces point mutations into the BCR sequence.  Thus, B cell clonal lineages 
can contain cells with BCR sequences that vary by only one or a few mutations. 
V(D)J recombination occurs in the bone marrow for B cells and the thymus for T 
cells. As their receptors are being rearranged, B and T cells that produce BCRs and TCRs 
that bind to self-antigens are negatively selected, albeit with less than 100% efficiency. 
TCRs are further positively selected to weakly associate with MHC molecules. This 
results in a primary immune repertoire that is imperfectly devoid of self-reactive 
antibodies and TCRs that are otherwise random in their specificity. 
T cells can be broadly separated into two major classes: CD4+ T cells and CD8+ T 
cells. CD4+ T cells are generally restricted to peptide-MHC class II complexes (pMHC-
II). MHC-II are expressed on some antigen presenting cells (APCs) and are loaded with 
peptides sourced from external proteins. For example, a dendritic cell – one of the key 
components of the innate immune system – uptakes bacterial proteins through 
phagocytosis. These proteins are then digested into peptide fragments around 11 – 30 
amino acids long and loaded onto MHC-II molecules to form pMHC-II complexes. A 
CD4+ T cell specific for that bacterial peptide will bind to the pMHC-II complex and 
initiate downstream signaling to trigger a response. CD4+ T cells carry out a wide range 
of functions, including helping B cells evolve higher affinity antibodies, activating 
macrophages, and suppressing inappropriate immune responses (e.g. autoimmunity). 
They are referred to as “helper T cells” due to their role in assisting the other branches of 
the immune system. 
CD8+ T cells are restricted to pMHC class I (pMHC-I) complexes which are 
expressed on almost all nucleated cells within the body. Cells that express MHC-I are 
constantly sampling the proteins within the cell itself. A portion of the proteins being 
produced within the cell are digested into peptide fragments around 8 – 11 amino acids 
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long and loaded onto MHC-I molecules. These pMHC-I complexes on the surface of the 
cells serve as an auditing system for protein production within the cell. As CD8+ T cells 
that express TCRs that bind to MHC-I molecules loaded with peptides derived from 
proteins produced in host cells under normal conditions are (mostly) negatively selected, 
if a CD8+ T cell does bind to a pMHC-I on the surface of a cell, then something must be 
awry. For example, a virally-infected cell suddenly produces viral proteins. A subset of 
these proteins are digested, loaded onto MHC-I molecules, and presented on the surface. 
As these peptides derived from viral proteins are not contained in the set of peptides that 
CD8+ T cells are negatively selected on, by chance, some CD8+ T cell in the TCR 
repertoire will express a TCR that binds to this pMHC-I complex. The bound CD8+ T cell 
indicates that there are inappropriate proteins within the cell, so the CD8+ T cell releases 
granzymes and perforin to kill off the potentially infected cell. In that sense, CD8+ T cells 
audit protein product within cells, and the punishment for failing an audit is the death 
penalty. Effector CD8+ T cells are thus named cytotoxic T lymphocytes (CTLs) for their 
ability to kill host cells.  
1.2 IMMUNOLOGICAL MEMORY AND LYMPHOCYTE DIFFERENTIATION 
The defining characteristic of the adaptive immune system is its ability to respond 
faster and with more fervor upon repeated exposure to an antigen9. In essence, the 
adaptive immune system is able to “remember” past infections, hence the term 
“immunological memory.” This capacity is rooted in the V(D)J recombination process 
described above and the unique receptors expressed on naive B and T cells. The antibody 
and TCR repertoires contain hundreds of billions, if not more, of different antibody and 
TCR sequences. During a primary infection, probabilistically there will be naive B and T 
cells that are specific for the invading pathogen. However, these antigen-specific naive B 
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and T cells are rare. As they traffic throughout the lymphatic system, there is a lag phase 
before the antigen-specific naive cells encounter the antigen, usually in draining lymph 
nodes, and begin mounting a response. Once activated, the naive cells can proliferate and 
differentiate into effector phenotypes. Activated B cells can differentiate into 
plasmablasts and plasma cells and begin to secrete their antigen-specific antibodies. 
Activated T cells can differentiate into cytokine-producing effector T cells and CTLs. 
Even after the lag phase, the magnitude of the immune response to an initial infection is 
relatively low, as measured by the concentration of circulating antibodies specific to the 
pathogen. It can take weeks for this response to peak.  
A subset of the progeny of the activated B and T cells during a primary infection 
differentiate into memory phenotypes which can persist for decades. Having already 
engaged antigen during the primary infection, these memory cells are primed and ready 
for a secondary infection. Upon reactivation, these memory cells differentiate into 
effector phenotypes in an accelerated manner. There is no lag phase during the secondary 
infection, and the magnitude of the response is greatly increased over the primary 
response. 
The fate of activated B cells during and after an infection is an area of active 
research10. On the surface level, proliferating B cells enter one of three phenotypes. 
Short-lived plasma cells differentiate with minimal SHM. These cells are quick to 
develop and secrete antibodies, and they die off after the infection has been cleared. On 
the other hand, long-lived plasma cells go through SHM and affinity maturation. These 
cells traffic to the bone marrow where they can reside for many years while constitutively 
secreting higher affinity antibodies. Long-lived plasma cells serve as the first line of 
defense against a secondary infection, as the antibodies already present in the blood can 
neutralize an infectious agent before it is able to take hold. Lastly, activated B cells can 
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differentiate into memory B cells. Memory B cells have been observed in individuals 90 
years after primary infection11. Unlike long-lived plasma cells, memory B cells circulate 
throughout the lymphatic system and peripheral blood until the come back into contact 
with their target antigens. Then, they can quickly differentiate into plasma cells to secrete 
high concentrations of antibodies. 
While they are part of the immune network which is intricately connected, the 
primary role of most B cell phenotypes is to secrete antibodies to fight infections. T cells, 
on the other hand, have a much more nuanced and diverse role. The differences between 
CD4+ and CD8+ T cells highlighted above only begin to scratch the surface of this 
heterogeneity. This is reflected in the large number of T cell memory subsets with 
varying functionalities. T cells are often categorized by their migratory patterns and 
cytokine expression profiles12. Central memory T cells (TCM) express CCR7 and CD62L 
and home to secondary lymphoid tissues. Effector memory T cells (TEM) lack CCR7 and 
CD62L expression and tend to circulate through the periphery. Tissue resident memory T 
cells (TRM) reside directly in tissues likely to be exposed to pathogens, such as the lungs, 
skin, and gut mucosa. TCM retain a naive-like stemness in their ability to proliferate 
rapidly when activated, while TEM are skewed more towards effector function and are 
more proficient at releasing cytokines.  
CD4+ T cells are particularly heterogeneous13. Depending on the cytokine context 
in which naive CD4+ T cells are activated, they can skew their cytokine expression 
profiles. IFN-γ and IL-12 lead to upregulation of T-bet which is the master transcription 
factor of the TH1 phenotype. TH1 cells predominantly produce IFN-γ and IL-2 and work 
to activate macrophages and CD8+ T cells. IL-4 and IL-2 promote GATA3 upregulation 
which leads to a TH2 phenotype. TH2 cells produce IL-4 which drives B cell proliferation 
and encourages isotype switching.  TGF-β and IL-6 lead to RORγt upregulation which 
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governs the TH17 response. TH17 cells produce IL-17 which has broad, proinflammatory 
functionality. An important subset of CD4+ T cells, regulatory T cells (Tregs) express the 
transcription factor Foxp3 and produce IL-10 and TGF-β to abrogate inappropriate 
immune responses. Tregs are largely responsible for limiting autoimmunity.  
Finally, follicular helper T cells (TFH) are specialized CD4
+ T cells that provide 
help to germinal center B cells14. Bcl-6 serves as the master regulator transcription factor 
for TFH cells, inhibiting the expression of T-bet, GATA3, and RORγt of other 
differentiation pathways. TFH express the chemokine receptor CXCR5 which leads to 
migration towards CXCL13 produced in the B cell follicles within lymph nodes. Thus, 
TFH colocalize with activated B cells within the B cell follicle and spur the formation of 
germinal centers. TFH express several costimulatory molecules, such as CD40L, SAP, 
ICOS, OX40, and PD-1 which interact with CD40, SLAM, ICOSL, OX40L, and PD-
L1/2 on activated B cells, respectively, to aid in germinal center B cell proliferation, 
maturation, class switching, and survival. TFH produce IL-21 and IL-4 which further drive 
germinal center B cell development into plasma cells and memory B cells. It is becoming 
increasingly clear that even within these specialized CD4+ T cell subsets there is much 
diversity. 
1.3 IMMUNE SYSTEM DEVELOPMENT WITH AGE 
The immune system beings to develop in the fetus and continues well into 
adolescence before settling into adult-like properties after puberty. Understanding the 
immune system’s evolution with age and capacity to fight pathogens is critical in our 
quest to lower infant mortality and improve health standards, as infections are one of the 
leading causes of death in young children worldwide. The various cogs of the immune 
system develop with different kinetics. As these cogs must work together in unison to 
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provide protection, minor changes in one aspect may have wide-ranging effects on the 
immune system as a whole. Drug interventions that are suitable for adults may not be 
optimal for infants depending on the developmental stage of their immune systems. 
Better knowledge of these stages of development could lead to more treatment options 
tailored to the specific stages which in turn could lead to better clinical outcomes. For 
example, the currently most advanced malaria vaccine, RTS,S/AS01, has been observed 
to be protective in only 18% of cases in young infants, compared to 28% in children15, 
leaving much room for improvement. Discovering the exact source of this 10% 
discrepancy is the first step to overcoming it. Studying the immune system at different 
life stages has the potential to unlock new therapies that compensate for inherent 
deficiencies. 
These inherent deficiencies are widespread throughout both the innate and 
adaptive immune cells16. With respect to the innate immune system, neutrophils arise in 
utero and reach adult-like counts within days of birth, but they are functionally impaired. 
Neutrophils have reduced phagocytic capabilities at birth, but they are quickly restored 
within 3 days17. However, neonatal neutrophils are also deficient in CD11b expression 
and exhibit reduced rolling and adhesive functions until 11-12 months of age18, 19. 
Despite similar cell counts, preterm neonatal plasmacytoid dendritic cells secrete 
significantly less IFN-α in response to TLR9 engagement, likely contributing to their 
exacerbated symptoms during viral infections such as RSV, HSV, and CMV20. 
On the adaptive side, neonatal CD4+ T cells are predisposed towards Treg and TH2 
phenotypes16. This leads to more tolerance and a weaker cell-mediated response to 
foreign pathogens. Neonatal B cells express lower levels of B7-1/2 and CD40, while 
neonatal T cells express lower levels of CD40L upon activation, likely contributing to 
impaired humoral immunity21. Infant B cells are particularly unresponsive to T-cell-
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independent antigens. This response is largely driven by splenic marginal-zone B cells 
which do not appear in significant numbers until 1-2 years old22. Germinal center 
formation may also be impaired in young infants, diminishing the B cell response to T-
cell-dependent antigens as well23. Overall, many facets of the infant immune system are 
still works in progress at birth, but the implications of these deviations from adult-like 
features are not fully elucidated. 
1.4 IMMUNE REPERTOIRE SEQUENCING 
The advent of high-throughput sequencing technologies has opened the door to a 
new dimension of research in biology24. Cheaper and cheaper access to technology 
capable of generating millions to billions of sequencing reads has redefined the term “Big 
Data,” and the implications have only just begun to be explored. Within the realm of 
immunology, high-throughput sequencing platforms like the Illumina MiSeq have 
kickstarted the field of Immune Repertoire Sequencing (IR-Seq). IR-Seq experiments 
seek to characterize the antibody and/or TCR repertoire via high-throughput sequencing 
of the multitude of diverse antigen receptors generated through V(D)J recombination.  
Early antibody sequencing experiments were limited to only dozens of 
sequences25. Given the sheer number of possible V(D)J rearrangements, junction 
insertions/deletions and SHM notwithstanding, characterizing the antibody repertoire to 
any meaningful depth was impossible. However, as technology improved and this 
restriction was lifted, another issue arose: sequencing errors. As discussed in section 1.1, 
clonal expansion and SHM can lead to related antibody sequences that vary by only one 
or a few mutations.  The reported error rate for Illumina MiSeq is about 0.5% errors per 
bp26. For an antibody sequencing read over 200bp long, this equates to 1 error per 
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sequencing read on average. Thus, distinguishing between genuine mutations and 
sequencing errors is a nontrivial task. 
IR-seq experiments tend to follow a similar basic framework. Most begin with 
reverse transcription of antibody or TCR mRNA, though some utilize genomic DNA. The 
resulting cDNA (or genomic DNA) must then be amplified to generate enough material 
for sequencing. This is achieved through many cycles of PCR, which can lead to 
amplification bias and PCR errors that further confound the inherent sequencing errors. 
Adaptors necessary for integration with the sequencing platform are added through PCR 
with overhanging primers to generate the final sequencing library. 
Molecular identifiers (MIDs) have been used to mitigate PCR and sequencing 
errors to overcome this pitfall of early next-generation antibody repertoire sequencing 
experiments27, 28, 29, 30. MIDs are short stretches of randomized DNA sequences that are 
tagged to individual cDNA molecules during reverse transcription and/or second strand 
synthesis. This can be achieved by fusing the randomized MIDs to the reverse 
transcription primer followed by a common sequencing adaptor sequence. The 
sequencing adaptor is then used for downstream PCR amplifications such that the 
randomized MID is conserved for each cDNA molecule that originated from the same 
mRNA transcript. Sequencing reads are then grouped according to the MID, and 
consensus sequences are built by taking the average nucleotide at each position. This 
essentially averages out PCR and sequencing errors that plagued early high-throughput 
IR-Seq experiments. For example, consider a single antibody mRNA transcript 
represented by 5 sequencing reads. Each raw read is inflicted by a different sequencing 
error. Without MIDs, these 5 sequencing reads would appear to be 5 distinct, clonally 
related antibody sequences. However, each of the 5 reads has the same MID, so they can 
be grouped together. For each of the 5 sequencing errors, the other 4 reads have the 
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correct nucleotide, so the consensus sequence constructed by averaging the sequencing 
reads will have the correct full-length antibody sequence. MIDs cannot compensate for 
errors during reverse transcription, but they provide the accuracy necessary for high 
quality repertoire characterization.  
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Chapter 2: Molecular Identifier Clustering-based Immune Repertoire 
Sequencing1 
2.1 INTRODUCTION 
V(D)J recombination creates hundreds of billions of antibodies and T cell 
receptors that collectively serve as the immune repertoire to protect the host from 
pathogens. Somatic hypermutation (SHM) further diversifies the antibody repertoire, 
which makes it impossible to quantify this diversity with nucleotide resolution until the 
development of high-throughput sequencing-based Immune Repertoire Sequencing (IR-
Seq)1, 2, 3, 4. Although we and others have developed methods to control for artifacts from 
high amplification bias and sequencing error rates through data analysis3, 5, 6, 7, 8, 9, 
obtaining accurate sequencing information has now been made possible by the use of 
molecular identifiers (MID)10, 11, 12, 13. MIDs serve as barcodes to track genes of interest 
through amplification and sequencing. They are short stretches of nucleotide sequence 
tags composed of randomized nucleotides that are usually tagged to cDNA during reverse 
transcription to identify sequencing reads that originated from the same mRNA transcript. 
There still lacks a general framework with respect to both experimental design 
and bioinformatics analysis on how to use MIDs, for example: what is the minimum cell 
input amount, how to efficiently use MIDs to tag each transcript, how to group reads to 
generate consensus sequences, and what quality metrics one can use to check their IR-
Seq methods. Answers to these questions are important for overall experiment design, 
repertoire diversity estimates, and controlling the accuracy of the sequence information 
                                                 
1Wendel, et al. Accurate Immune Repertoire Sequencing Reveals Malaria Infection Driven Antibody 
Lineage Diversification in Young Children. Nature Communications, accepted. B.S.W. performed naive B 
cell isolation and data analysis; C.H. helped with sequencing data analysis; M.Q. developed the sequencing 
protocol using sorted naive B cells; D.W. developed the pipeline; P.R. provided computation resources and 
helped with analysis; N.J. conceived the idea, designed the study, and directed data analysis; B.S.W. and 
N.J. wrote the paper with contributions from all co-authors.  
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obtained. Despite recent advancements, the large amount of input RNA required and low 
diversity coverage make it challenging to analyze small numbers of cells, such as 
memory B cells from dissected tissues or blood draws from young children, using IR-Seq 
because these samples require many PCR cycles to generate enough material to make 
sequencing libraries, thus exacerbating PCR bias and errors. 
Here, we report the development of MID clustering-based IR-Seq (MIDCIRS) 
that further separates different RNA molecules tagged with the same MID. Using naive B 
cells, we demonstrate that MIDCIRS has a high coverage of the diversity estimate, or 
different types of antibody sequences, that is consistent with the input cell number and a 
large dynamic range of three orders of magnitude compared to other MID-based immune 
repertoire sequencing methods10, 11. Given the wide use of IR-Seq in basic research as 
well as clinical settings, we believe the method outlined here will serve as an important 
guideline for future IR-Seq experimental designs. 
2.2 RESULTS 
2.2.1 Overview of the MIDCIRS method 
MIDs have been used to track individual RNA molecules through PCR and 
sequencing in IR-Seq to reduce error rate10, 11, 12, 13. They can be designed with sufficient 
length, and thus diversity, to tag each individual molecule uniquely. However, this 
requires knowledge of the total number of RNA molecules in the sample, which requires 
a significant amount of time and effort to measure for each sample before library 
preparation. Longer MIDs are likely to decrease the reverse transcription efficiency14, 15. 
Therefore, we fixed the MID length at 12 random nucleotides and developed a 
generalized approach to identify each individual transcript using a sequence-similarity-
 16 
based clustering method to separate a group of sequencing reads with the same MID into 
sub-groups (Figure 2.1). 
 
 
Figure 2.1: MIDCIRS overview. (a) Schematic overview of tagging single antibody 
transcripts with MIDs. (b) Schematic overview of the informatics pipeline 
of MIDCIRS which includes merging paired-end reads, performing 
clustering to generate MID sub-groups, and building consensus sequences. 
In brief, we tag MIDs to cDNA during reverse transcription by fusing the 12N 
MIDs and a partial sequencing adaptor to antibody heavy chain constant region-specific 
primers. We then use multiplexed primers complementary to the 5’ end of the antibody V 
gene alleles fused to another partial sequencing adaptor to amplify the cDNA in the 1st 
PCR step. We perform a 2nd PCR step to ligate the full adaptor sequences before gel 
purifying, quantifying, and sequencing the library on the Illumina MiSeq 2x250 platform. 
Primers used for library generation can be found in Table A.1. The resulting paired-end 
sequencing reads are merged, and antibody reads are identified. Antibody reads are then 
grouped according to MID, and then each MID is split into sub-groups by clustering on 
sequence similarity. This clustering step separates distinct RNA molecules that, by 
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chance, were labeled with the same MID during reverse transcription. Consensus 
sequences are then built by taking the average nucleotide at each position within a sub-
group, weighted by the quality score. Each consensus sequence represents an mRNA 
molecule, and identical consensus sequences are merged into unique consensus 
sequences, or unique RNA molecules. 
2.2.2 Sub-group clustering threshold determination 
The clustering threshold for sub-group generation must be lenient enough to 
group reads that differ due to PCR and sequencing errors into the same MID sub-group 
but stringent enough to exclude reads that are derived from different antibody sequences. 
We used RNA controls with known sequences to ensure the Levenshtein distance 
threshold (number of substitutions, insertions, or deletions required to match 2 strings) 
was lax enough to group 99% of the control sequences together. For both control 
templates, this was achieved at a Levenshstein distance of 23 for a 150bp sequence, so 
the clustering threshold was set to 15% of the read length (Figure 2.2a). To test whether 
this threshold was strict enough to prevent distinct antibody sequences from grouping 
together, we used a library of 106 FACS-sorted naive B cells and plotted the percentage 
of MID groups with multiple sub-groups at varying clustering thresholds (Figure 2.2b). 
At 0% clustering threshold, a single PCR or sequencing error would result in sub-group 
formation, so the percentage of MID groups containing multiple sub-groups is at a 
maximum. By 60% clustering threshold, even antibody sequences utilizing different V, 
D, and J genes can be grouped together, so the number of MIDs with multiple sub-groups 
approaches 0, and the clustering step loses distinguishing power. The 15% clustering 
threshold occurs just before the steep drop in the sigmoidal curve, indicating that it is 




Figure 2.2: Sub-group clustering threshold calibration. (a) Cumulative percentage of 
reads as a function of the Levenshtein distance between the RNA control 
templates and sequencing reads. The lengths of the control templates and 
reads were 150bp. (b) Percentage of MIDs with multiple sub-groups as a 
function of the clustering threshold.  
2.2.3 MIDCIRS yields high accuracy and coverage down to 1000 cells 
We used FACS-sorted naive B cells with varying numbers (103 to 106) to test the 
dynamic range of MIDCIRS. Overall, 95% of the sequencing reads were successfully 
merged, and of those 98% were assigned as antibody sequences (Table 2.1). These 
percentages were generally higher at larger cell inputs, but the absolute number of 
erroneous reads at low cell counts was miniscule in terms of cost and computational 
resources.  
Our digital PCR results (not shown) give a lower end of 10 antibody RNA copies 
per naive B cell. With 30% RNA input, for 106 naive B cells, this yields 3x106 antibody 
RNA molecules being tagged by 412 MIDs. Poisson statistics predicts that 8.5% of the 
MIDs would tag 2 or more different RNA molecules. This model closely matches our 
experimental results, with 7.1% of the MIDs in the 106 naive B cell library containing 
 19 
multiple sub-groups. Without the sub-group clustering step of MIDCIRS, these 7.1% of 
MIDs would either be discarded or lead to incorrect consensus sequence formation. As 
expected, the number of MIDs containing multiple sub-groups decreases with decreasing 



















1,000 46,320 22,742 9,201 797 94.30 1 
2,000 44,846 18,602 17,421 2,176 93.29 2 
10,000 228,711 99,370 62,242 7,102 94.73 9 
20,000 293,279 196,570 184,754 23,991 93.27 49 
100,000 1,153,763 1,074,771 1,048,523 165,663 92.63 1,137 
200,000 2,191,738 2,107,762 2,059,944 404,225 91.41 7,239 
1,000,000 7,494,809 7,342,163 7,258,253 1,516,098 86.44 108,172 
Table 2.1: Sequencing reads statistics for naive B cell libraries. aA useful MID has more 
than two reads. If there are only two reads in an MID, they are discarded 
unless they are identical. bThe number of MIDs containing sequences 
derived from 2 or more different antibody sequences. 
An important but often overlooked parameter for IR-Seq experiments is the 
diversity coverage, or the percentage of the maximum number of unique sequences 
discovered. While a lack in diversity coverage can be overcome by increasing the cell 
input to obtain enough sequences for comprehensive repertoire analysis, this is not 
always possible with precious samples and rare cell types, for example memory B cells 
sorted from infants from whom only 4mL of blood can be ethically drawn, and memory 
B cells are rare (see Chapter 3). To estimate the diversity coverage of MIDCIRS, we 
plotted the number of unique RNA molecules discovered against the cell input number 
(Figure 2.3a).  The results displayed a strong correlation with cell numbers at 83% 
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coverage (Figure 2.3a, slope). Previous studies have shown that about 80% of naive B 
cells express distinct heavy chain genes16, 17, thus our method achieves a comprehensive 
diversity coverage that is much higher than other MID-based antibody repertoire 
sequencing techniques10, 11, 12, 13 .  
Next, we examined the error rate with or without using MIDCIRS. Because the 
diversity among hundreds of millions of antigen receptors lies in a short stretch of DNA 
about 60 nucleotides, often two distinct sequences differ by only a few nucleotides. In 
addition, somatic hypermuation, a process that further diversifies antibody sequences, has 
a mutation rate that is comparable to the error rate of the next-generation sequencers. 
This makes estimating the total antigen receptor diversity and tracing the mutational 
evolution of antibody sequences difficult. We calculated the raw read error rate without 
MIDCIRS by comparing the individual reads within a sub-group to the consensus 
sequence and reached a similar rate as previously reported for Illumina sequencing, about 
0.5%18 (Figure 2.3b, top panel). To calculate the improved error rate using MIDCIRS, 
we split the total reads into two groups, performed clustering separately, and then 
compared the consensus of overlapping sub-groups from these two sub-samples. The 
resulted error rate was 130-fold lower than the raw error rate (Figure 2.3b, bottom 
panel). In addition, while the raw error rate fluctuated between the 3 runs (Figure 2.3b, 
top panel), the improved error rate after using MIDs remained constant (Figure 2.3b, 
bottom panel). Taken together, these results demonstrate that MIDCIRS can cover a large 






Figure 2.3: MIDCIRS yields high diversity coverage with low error rate. (a) Correlation 
between number of cells and number of unique RNA molecules after using 
MIDCIRS. RNA from as few as 1,000 to as many as 1,000,000 naive B cells 
was used as input material in generating the amplicon libraries. Slope 
indicates the estimated diversity coverage. (b) Comparison between raw 
error rate and improved error rate after using MIDCIRS. Raw reads error 
rates (top, blue) and MIDCIRS consensus error rates (bottom, red) for 3 
Miseq runs, calculated as described in Methods 2.4.5. 
2.2.4 MIDCIRS is robust and mitigates artificial diversity 
Sequencing depth is another important factor to consider when designing an IR-
Seq experiment. In order to utilize MIDs to reduce the error rate, IR-Seq libraries must be 
sequenced deep enough to ensure that most MIDs have at least 2 reads associated with 
them. Consensus building cannot be performed on a single read, so MIDs with only a 
single read must be discarded, as they are plagued by the inherently high raw reads error 
rate shown in Figure 2.3b. Here, we sequenced each library to a depth of 5 times the cell 
input number and found that 92% of the reads had useful MIDs (Table 2.1). While 
suitable for these FACS-sorted naive B cell libraries, the optimal sequencing depth varies 
depending on the sample type and number of antibody transcripts. More antibody 
transcripts will require more reads in order to saturate.   
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As a generalized approach to IR-Seq experimental quality control and sequencing 
depth check, we performed rarefaction analysis by subsampling the sequencing reads to 
different amounts and then computing the diversity to test the effect of sequencing depth 
and error rate on MIDCIRS. On average, the rarefaction curves reach a plateau at a 
sequencing depth of around three times the cell number using MIDCIRS, suggesting that 
sequencing more will not discover further diversity (Figure 2.4a).  In contrast, without 
using MIDCIRS, the number of unique sequences continues to increase well beyond the 
number of cells for all samples (Figure 2.4b). This artificial diversity from 
oversequencing is a result of PCR or sequencing error-inflicted sequences being 
discovered which were hidden at lower sequencing depth due to their relative rarity. 
These rare errors are averaged out during consensus building, so MIDCIRS effectively 
mitigates artificial diversity. The optimal sequencing depth is likely to change depending 
on sample composition, so rarefaction analysis should be performed on every newly 







Figure 2.4: Rarefaction analysis for optimal sequencing depth. Rarefaction analysis for 
each library with (a) and without (b) using MIDCIRS. Inset displayed 
zoomed-in view near the origin for low cell count libraries. NBCs, naive B 
cells. 
2.3 DISCUSSION 
IR-Seq has been very useful to study the immune response in both research and 
clinical settings19, 20. However, the first generation of IR-Seq suffered from high PCR and 
sequencing errors, making it hard to distinguish true somatic hypermutations from errors 
or true CDR3 diversity from artifacts. In addition, the IR-Seq field lacks a general 
framework that one can follow when designing and validating any new IR-Seq methods. 
In this study, we described a new IR-Seq method, MIDCIRS, which separates different 
RNA molecules that might have been labeled with the same MIDs into different sub-
groups. This method is robust, accurate, and suitable for analyzing small amount of cell 
input, while correcting undercounted diversity.  
Ensuring that each MID only labels one specific RNA molecule requires prior 
knowledge of the total antibody RNA transcript number in the sample, which takes time 
and resources to measure and requires using a portion of the RNA material which could 
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otherwise be used for other experiments to maximize the data output from precious 
samples. Here, we demonstrated that, by using clustering based on MID groups, we can 
identify new diversities, and this corrected diversity matches cell input numbers very 
well. We showed that when input cell numbers are low, most of the MIDs contain only 
one type of heavy chain transcript. However, as the cell number increases, there are more 
MIDs containing more than one type of antibody heavy chain transcript. For 106 naïve B 
cells, 108,172 out of 1,516,098 useful MIDs (7.1%) tagged 2 or more unique RNA 
molecules. Without sub-group clustering, the diversity of this library would be 
significantly undercounted. This number is likely to increase if more cells are used as an 
input material or B cells containing high antibody transcript counts constitute a 
significant portion of the input material, such as plasmablasts in PBMC samples after 
vaccination. Therefore, directly building consensus using MIDs is likely to underestimate 
the total diversity. Using our MIDCIRS method, we analyzed data from a recent 
publication11 where the same number of random nucleotides (12N) was used. Using the 
same criteria defining unique CDR3 sequences, our MIDCIRS analysis showed that 
about 5% of the diversity was undercounted because sequencing reads from multiple 
distinct RNA molecules that were tagged with the same MID were counted as one type of 
RNA by Shugay et al11, highlighting the necessity of the clustering method we developed 
in MIDCIRS. 
In summary, we presented a new method of utilizing MIDs to significantly 
improve the accuracy and robustness of the IR-Seq and approaches that one can 
incorporate into their experiment designs to QC the method and analyses. We believe that 




2.4.1 Sample collection and isolation 
Human PBMCs were purified from de-identified blood bank donor samples using 
conventional Ficoll density gradient centrifugation. This protocol was approved by the 
Institutional Review Board of the University of Texas at Austin as non-human subject 
research. Naive B cells were FACS-sorted at varying cell counts (103 to 106) based on the 
phenotype of CD3–CD19+CD20+CD27–CD38low. The following antibody clones were 
obtained from Biolegend and used as 1:25 dilution: Alexa Fluor 488 OKT3 (CD3), 
Pacific Blue 2H7 (CD20), Brilliant Violet 605 O323 (CD27), and APC-Cy7 HIT2 
(CD38). Flow cytometry and cell sorting were performed on BD FACS Aria II. 
2.4.2 Bulk antibody sequencing library generation and sequencing 
MIDs were added during the reverse transcription step through the use of fusion 
primers, which contain the partial Illumina P5 sequencing adaptor followed by twelve 
random nucleotides and primers to the constant region of five antibody isotypes. We 
fused eleven forward primers that were previously designed6 to partial Illumina P7 
adaptor. Full Illumina adaptors were added during the second PCR step along with library 
indexes. Total RNA was purified using All Prep DNA/RNA kit (Qiagen) following the 
manufacturer’s protocol. cDNA synthesis was done using Superscript III (Life 
Technologies) with 30% of the RNA as input. After free primer removal by Exonuclease 
I digestion (New England Biolabs) according to the manufacturer’s protocol, Takara Ex 
Taq HS polymerase (clone Tech) was used for both PCR reactions. The first PCR was 
performed with the following program: initial denature at 95C for 3 minutes, followed 
by 20 cycles of 95C for 30 seconds, 57C for 30 seconds, and finally 72C for 2 minutes 
with a 4C hold. All cDNA was used for first PCR and about 1% of 1st PCR product was 
 26 
used for second PCR. The second PCR was performed with the following program: initial 
denature at 95C for 3 minutes, followed by 10 cycles of 95C for 30 seconds, 57C for 
30 seconds, and finally 72C for 2 minutes with a 4C hold. The second PCR products 
were gel purified and quantified by qPCR Library Quantification Kit (KAPA biosystems, 
catalog number KK4824). 0.009 pmol of the QCed second PCR product were  sequenced 
on Illumina Mi-seq with paired-end 250bp read mode (sequencing kit catalog number: 
MiSeq Reagent Kit v2 (500cycle) MS-102-2003).  The list of primers for RT and PCR 
can be found in Table A.1. Libraries were sequenced multiple times until saturated based 
on rarefaction analysis in Figure 2.4. Reads from all runs were combined and analyzed. 
2.4.3 Preliminary read processing 
Raw reads from Illumina MiSeq PE250 were first cleaned up following steps 
outlines in Figure 2.1b. Only reads that exactly matched the corresponding library 
indices were included for further processing. The end of each raw read was trimmed such 
that all bases had a quality score of 25 or higher.  Reads 1 and 2 were merged using the 
SeqPrep tool (https://github.comjstjohn/SeqPrep). The merged reads were filtered with 
specific V-gene and constant region primers to determine antibody reads. The primers 
were then truncated from the reads. The retained reads were further truncated to 320bp. 
Read numbers after each filter are listed in Table 2.1. 
2.4.4 MID sub-group generation 
Raw reads were split into MID groups according to their 12 nucleotide barcodes. 
For each MID group, quality threshold clustering was used to cluster similar reads. This 
process groups reads derived from a common template RNA molecule together while 
separating reads derived from distinct RNA molecules. A Levenshtein distance of 15% of 
the read length was used as the threshold. This was calibrated using RNA controls with 
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known sequences (Figure 2.2). For each sub-group, a consensus sequence was built 
based on the average nucleotide at each position, weighted by the quality score. In the 
case that there were only two reads in an MID sub-group, we only considered them useful 
reads if both were identical. Each MID sub-group is equivalent to an RNA molecule. 
Next, we merged all of the identical consensus to form unique consensus sequences, or 
unique RNA molecules, which were used to estimate the diversity and assess the 
sequencing depth in rarefaction analysis (Figure 2.4). Scripts for this section can be 
downloaded at https://github.com/utjianglab/MIDCIRS. 
2.4.5 Error rate calculation 
The difference between the consensus sequence for an RNA molecule and the raw 
reads associated with it represent the errors generated in either PCR or sequencing. The 







    (2.1) 
 
where Diff(i,I) is the Levenshtein distance between read i and the consensus sequence in 
MID sub-group I, 𝑁𝐼 is the number of reads in MID sub-group I, and L is the read length.  
In order to estimate the improved error rate using MIDCIRS, we equally divided 
the raw reads from one library into two datasets. The same MID sub-group generating 
process was performed on both datasets. By comparing the differences between the 
consensus sequences with identical MID between these two datasets, we can calculate the 
improved error rate for using MID sub-groups as: 
 
  𝐸𝑟𝑟𝑜𝑟𝑅𝑎𝑡𝑒(𝑀𝐼𝐷) =
∑ 𝐷𝑖𝑓𝑓(𝐼,𝐽)𝐼,𝐽 ×𝑁𝐼
∑ 𝑁𝐼𝐼 ×𝐿
    (2.2) 
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where Diff(I,J) is the Levenshtein distance between the consensus I and consensus J 
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 Chapter 3: Accurate Immune Repertoire Sequencing reveals malaria 
infection-driven antibody lineage diversification in young children2 
3.1 INTRODUCTION 
The immune system, similar to the vessel that houses it, develops with age1. 
Infants are born fragile and vulnerable. All of the parts are present – eyes, ears, B cells, T 
cells – but they are not fully matured. While the maturation of the physical body is 
obvious, the maturation of the immune system is more subtle. Some components of the 
innate immune system, such as neutrophils and pulmonary macrophages, reach adult-like 
levels within days of birth but exhibit reduced functionality2, 3. Aspects of the adaptive 
immune system are also impaired early in life. B cell responses to T cell-independent 
polysaccharide antigens are notably impaired until 1-2 years of age, and antibody 
responses to T cell-dependent antigens are also diminished in infants4. During this time, 
infants routinely receive vaccines and are exposed to environmental antigens. Umbilical 
cord blood provides a noninvasive biospecimen to sample the newborn immune system; 
however, the post-birth development of the immune system is not well characterized due 
in large part to the limited sample size availability. In particular, there lacks a 
comprehensive analysis of the antibody repertoire changes that occur during a natural 
infection. 
                                                 
2Wendel, et al. Accurate Immune Repertoire Sequencing Reveals Malaria Infection Driven Antibody 
Lineage Diversification in Young Children. Nature Communications, accepted. B.S.W. performed all 
malaria related experiment and data analysis; C.H. performed BASELINe and other sequencing data 
analysis; M.Q. developed the sequencing protocol using sorted naive B cells; D.W. helped with sequence 
analysis; S.M.H. helped with library construction; K.Y.M. helped with sequencing; J.X. helped with 
lineage visualization, E.W.L, P.D.C., and S.K.P. selected malaria patients, provided samples and helped 
with experimental design; P.R. provided computation resources and helped with analysis; K.C. helped with 
lineage structure algorithm optimization and lineage visualization; N.J. conceived the idea, designed the 
study, and directed data analysis; B.S.W. and N.J. wrote the paper with contributions from all co-authors.  
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Here, we use MIDCIRS (See Chapter 2) to examine the antibody repertoire 
diversification in infants (<12 months old) and toddlers (12 – 47 months old) from a 
malaria endemic region in Mali before and during acute Plasmodium falciparum 
infection. Although the antibody repertoire in fetuses5, cord blood6, young adults7, and 
the elderly7, 8 has been studied, infants and toddlers are among the most vulnerable age 
groups to many pathogenic challenges, yet their immune repertoires are not well 
understood. Infants are widely thought to have weaker responses than toddlers to 
vaccines because of their developing immune systems9. Thus, understanding how the 
antibody repertoire develops and diversifies during a natural infection, such as malaria, 
not only provides valuable insight into B cell ontology in humans, but also provides 
critical information for vaccine development for these two vulnerable age groups. Using 
peripheral blood mononuclear cells (PBMC) from 13 children aged 3 to 47 months old 
before and during acute malaria, with two of the children followed for a second year and 
9 additional pre-malaria individuals we show that infants and toddlers use the same V, D, 
and J combination frequencies and have similar complementarity determining region 3 
(CDR3) length distributions. Although infants have a lower level of average SHM than 
toddlers, the number of SHMs in reads that mutated in infants is unexpectedly high. 
Infants have a similar, if not higher, degree of antigen selection strength, assessed by the 
likelihood of amino acid-changing SHMs, compared with toddlers. Remarkably, during 
acute malaria, antibody lineages expand in both infants and toddlers, and this expansion 
is coupled with extensive diversification to the same degree as in young adults in 
response to acute malaria10, 11. Furthermore, informatically reconstructing antibody clonal 
lineages using sequences from both pre-malaria and acute malaria samples from the same 
individuals shows that infants are capable of introducing SHMs upon a natural infection. 
This two-timepoint-shared lineage analysis reveals that memory B cells isolated from 
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pre-malaria samples in malaria-experienced individuals continue to induce SHMs upon 
acute malaria rechallenge and most IgM memory B cells maintain IgM, while a small 
fraction switch isotypes. In summary, using an accurate and high-coverage IR-Seq 
method, we discover features of the antibody repertoire that were previously unknown in 
infants and toddlers, shedding light on the development of the immune system and its 
interactions with pathogens.  
3.2 RESULTS 
3.2.1 Infants and toddlers have similar VDJ usage and CDR3 lengths 
Equipped with this ultra-accurate and high-coverage antibody repertoire 
sequencing tool, we applied it to study the antibody repertoire of infants and toddlers 
residing in a malaria endemic region of Mali. From an ongoing malaria cohort study12, 
we obtained paired PBMC samples collected before and during acute febrile malaria from 
13 children aged 3 to 47 months old (Figure 3.1 and Table B.1). Two of the children 
were followed for an additional year, giving 15 total paired PBMC samples. An average 
of 3.8 million PBMCs per sample were directly lysed for RNA purification. All PBMCs 
were subjected to MIDCIRS analysis. An average of 3.75 million sequencing reads were 
obtained for each PBMC sample (Table B.2).  
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Figure 3.1: Sample collection timeline. All pre-malaria blood draws were taken in May, 
just before the start of the rainy season. Acute malaria blood draws were 
taken 7 days after the onset of acute febrile malaria. Unless otherwise 
indicated (a), all samples were collected during 2011. Average precipitation 
was estimated from the neighboring city of Bamako, Mali 
(climatemps.com). * Same individual. † Same individual. a Drawn in 2012 
For all PBMC samples, sequencing approximately the same number of reads as 
the cell numbers saturates the rarefaction curves (Figure B.1). VDJ gene usage is highly 
correlated for IgM between infants and toddlers regardless of weighting the correlation 
coefficient by the number of sequencing reads or clonal lineages (Figure 3.2), 
demonstrating that the same mechanism of VDJ recombination is used to generate the 
primary antibody repertoire in infants and toddlers. Weighting on the number of clonal 
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lineages in each VDJ class increases the correlation for IgG and IgA compared with 
weighting on the number of reads in each VDJ class (Figure 3.2). The diagonal lines in 
each panel indicate same sample self-correlation, and the two shorter off-diagonal lines 
indicate correlations from two timepoints of the same individual. These data recapitulate 
previous observations from our study in zebrafish that clonal expansion-induced 
differences on the number of reads in each VDJ class can confound the highly similar 
VDJ usage during B cell ontology13. In addition, infants and toddlers have similar CDR3 
length distributions across the three isotypes and both timepoints (Figure 3.3), consistent 
with recent studies of PBMCs from 9 month olds infants5, 6 and adults14, 15 and 
confirming the previous results that an adult-like distribution of CDR3 length is achieved 





Figure 3.2:  Correlation between VDJ usage in paired PBMCs samples (N=15 pairs of 
pre-malaria and acute malaria). Correlations weighted by reads (a) or by 
lineage (b). The color bar left of each panel as well as in figure legend 
indicates the sample group: infant pre-malaria (pink), toddler pre-malaria 
(light green), infant acute malaria (maroon), and toddler acute malaria (dark 
green). Color indicates strength of Pearson correlation. The diagonal lines in 
each panel indicate same sample self-correlation; two shorter off-diagonal 
lines indicate correlations from two timepoints of the same individual. 
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Figure 3.3: Infants and toddlers have similar CDR3 length distributions. CDR3 amino 
acid lengths of infants (black, N=6) and toddlers (red, N=9) at pre-malaria 
(top) and acute malaria (bottom) timepoints, separated by isotype. 
3.2.2 Both infants and toddlers have unexpectedly high SHM loads 
SHM is an important characteristic of antibody repertoire secondary 
diversification due to antigen stimulation17. Although it has been demonstrated before 
that infants have fewer mutations in their antibody sequences than toddlers and adults, the 
limited number of sequences for only a few V genes does not provide convincing 
evidence of the levels of SHM in infants18. A recent study using the first generation of 
IR-Seq showed that two 9-month-old infants averaged at least 6 SHMs in IgM of an 
average length of 500 nucleotides5. These numbers are equivalent to, if not higher than, 
reported SHM rates in IgM sequences from healthy adults day 7 post influenza 
vaccination19 and are much higher than a low-throughput infant study using a few V 
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genes and limited antibody sequences20. Due to inherent errors associated with the first 
generation of IR-Seq as discussed above, it is possible that PCR and sequencing errors 
played a role5.  In addition, it remains unclear if infants (< 12 months old) are able to 
generate a significant number of mutations in response to infection, which would 
demonstrate their capacity to diversify the antibody repertoire21.  
Here, we show that infants (< 12 months old) and toddlers (12 – 47 months old) 
reach an unexpectedly high level of SHMs in all 3 major isotypes, particularly IgG and 
IgA22 (Figure 3.4). While the mutation distributions remain in the low end of the 
spectrum for IgM, the number of mutations is significantly higher in IgG and IgA for 
both age groups. The threshold for the 10% most highly mutated unique RNA molecules 
is around 10 in infant IgG and IgA sequences (Figure 3.4, Infants, right of the blue long 
vertical lines) and around 20 in toddler IgG and IgA sequences (Figure 3.4, Toddlers, 
right of the blue long vertical lines). To minimize any possible inflation of SHMs, we 
excluded all sequences that were mapped to novel alleles, which were identified by both 
TIgGER23 and inspecting IgM sequences (see Chapter 4). These putative novel alleles 
account for 8% of all unique sequences on average (Table B.3). Naive B cells from these 
same patients, sorted as a control, harbor only 0.55 mutations on average, as expected 
(Table B.4). Upon acute malaria infection, the SHM histogram shifts rightward for 
almost all isotypes in almost all individuals (Figure 3.4, the right shift of pink long 
vertical line compared to blue long vertical line), including infants. These results 
demonstrate high levels of SHM that exceed what have been documented previously20, 22. 
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Figure 3.4: Infants and toddlers are capable of generating highly mutated antibodies. 
Distribution of SHM number for infants (N=6) and toddlers (N=9), from 
whom we had paired pre-malaria (blue) and acute (pink) malaria samples, 
weighted by unique RNA molecules. Blue and pink long vertical lines 
represent the number of mutations above which 10% of sequences fall for 
the respective samples. * and † demarcate samples derived from the same 
individuals followed for 2 malaria seasons.  
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3.2.3 SHM load is distinct between infants and toddlers 
The differences in the shapes of SHM distributions of infants and toddlers, 
steadily decreasing from unmutated for infants in all three isotypes while peaking around 
10 for toddlers in IgG and IgA (Figure 3.4), suggest that the total SHM load might reflect 
the history of interactions between the antibody repertoire and the environment, including 
malaria exposure. Since the malaria season is synchronized with the 6-month rainy 
season (Figure 3.1), and > 90% of the individuals in this cohort are infected with P. 
falciparum during the annual malaria season12, we hypothesized that the SHM load 
would increase with age. However, we found that the SHM load rapidly increases with 
age in infancy and then appears to plateau around 12 months of age in an initial smaller 
set of children with paired pre-malaria and acute malaria PBMC samples (Figure B.2). 
We then added 9 pre-malaria samples around the infant and toddler transition (5 of 11 
months old and 4 of 13 to 17 months old). The two-staged trend of SHM load remains for 
all three isotypes (Figure 3.5), with samples around the transition having the largest 
variation. Detailed comparisons show that, consistent with the two-stage trend, toddlers 
have a higher SHM load compared with infants for all three isotypes at both pre-malaria 
and acute malaria timepoints (Figure 3.6, comparison between age groups). Although 
there is a significant increase on SHM load upon acute malaria infection in IgM for both 
infants and toddler, bulk PBMC analysis does not show a significant increase in IgG or 
IgA, possibly because of the already elevated SHM base level. This, along with the two-
stage trend (Figure 3.5), suggests that 12 months is an important developmental 
threshold for secondary antibody repertoire diversification: before this threshold, the 
global repertoire is quite naive but can quickly diversify upon a natural infection. 
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Figure 3.5: SHM load increases rapidly with age before reaching a plateau. Age-related 
average number of mutations in pre- (blue circle, N=24, NInfant=11, 
NToddler=13) and acute malaria (pink triangle, N=15, NInfant=6, NToddler=9) 
samples, weighted by RNA molecules, split by isotype. Dashed line 
indicates the age boundary for infants (<12 months old) and toddlers (12 – 
47 months old). 
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Figure 3.6: Comparison of average number of mutations for paired infants and toddlers. 
Pre- (blue) and acute (pink) malaria samples separated by isotype; lines 
connect paired samples (NInfant,paired=6, NToddler,paired=9). Bars indicate means. 
*P < 0.05, **P < 0.01, N.S. indicates no significant difference by two-tailed 
Mann-Whitney U test (between age groups, dashed lines) or two-tailed 
Wilcoxon Signed-Rank test (between paired timepoints, solid lines). 
Differences in variance were not significant by squared ranks test. 
3.2.4 Higher memory B cell percentage results in higher SHM load 
This unexpected developmental threshold of secondary antibody repertoire 
diversification prompted us to focus on B cell subset composition changes and ask 
whether they correlate with this two-staged SHM load. Flow cytometry analysis reveals 
that naive B cells decrease from about 95% in 3-month-old infants to about 80% in 
toddlers (Figure 3.7a). Conversely, memory B cells increase from about 4% in 3-month-
old infants to about 15% in toddlers (Figure 3.7f). As the two-stage SHM load analysis 
suggests, 12 months appears to divide the samples into two age groups, with a large 
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variation at the infant to toddler transition and in the toddler group. Infants have a 
significantly more naive B cells and fewer memory B cells than toddlers (Figure 3.7b,g). 
Plasmablast percentages fluctuated in a much smaller range (Figure B.3). With a similar 
two-staged trend observed for B cell subset percentages, we hypothesized that the B cell 
subset percentage would correlate with SHM load. Indeed, further analysis shows that the 
decrease in naive B cell percentage and the increase in memory B cell percentage 
correlate well with SHM load across IgM, IgG, and IgA isotypes (Figure 3.7c-e and h-j), 
which supports our initial hypothesis that 12 months separates infants from toddlers in 
both SHM load and B cell composition changes. These data suggest that memory B cells 
contribute significantly to the developing antibody repertoire, and their composition is 





Figure 3.7: Decrease of naive B cell and increase of memory B cell percentages show a 
two-stage trend and correlate with SHM load.  (a) Naive B cell percentages 
of total B cells from the pre-malaria samples (N=22) vary with age.  Dashed 
vertical line depicts the cutoff between infants and toddlers. (b) Naive B cell 
percentages of total B cells compared between infants (black, N=9) and 
toddlers (red, N=13). (c-e) Naive B cell percentages correlate with average 
number of mutations (SHM load) in IgM (c), IgG (d), and IgA (e) sequences 
from bulk PBMCs in pre-malaria samples (N=22). (f) Memory B cell 
percentages of total B cells from the pre-malaria samples (N=22) vary with 
age.  Dashed vertical line depicts the cutoff between infants and toddlers. (g) 
Memory B cell percentages of total B cells compared between infants 
(black, N=9) and toddlers (red, N=13). (h-j) Memory B cell percentages 
correlate with average number of mutations (SHM load) in IgM (h), IgG (i), 
and IgA (j) sequences from bulk PBMCs in pre-malaria samples (N=22). (b 
and g) Bars indicate means; **P < 0.01, ***P < 0.001, two-tailed Mann-
Whitney U test. (c to e and h-j) ρ and P values determined by Spearman’s 
rank correlation listed in each panel. 
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3.2.5 SHMs are similarly selected in infants and toddlers 
One of the key features of antibody affinity maturation is antigen selection 
pressure imposed on an antibody, which is reflected in the enrichment of replacement 
mutations24 in the CDRs, the parts of the antibody that interact with antigens, and the 
depletion of replacement mutations in the framework regions (FWRs), the parts of the 
antibody responsible for proper folding. The unexpectedly high level of SHMs observed 
in infants prompted us to ask whether those SHMs have characteristics of antigen 
selection, as seen in older children and adults. As previous studies have shown that 
infants have limited CD4 T cell responses and neonatal mice exhibit poor germinal center 
formation9, we hypothesized that infant antibody sequences would display weaker signs 
of antigen selection. Here, we use a recently published tool, BASELINe25, to compare the 
selection strength. BASELINe quantifies the likelihood that the observed frequency of 
replacement mutations differs from the expected frequency under no selection; a higher 
frequency implies positive selection and a lower frequency implies negative selection, 
and the degree of divergence from no selection relates to the selection strength. 
Surprisingly, despite infants harboring fewer overall mutations, these mutations are 
positively selected in the CDRs and negatively selected in the FWRs in both IgG and IgA 
(Figure 3.8b,c,e,f). Contrary to the hypothesis that infants would have a lower selection 
strength than toddlers, for both IgG and IgA, infants actually have a higher selection 
strength at both pre-malaria and acute malaria timepoints (Figure 3.8). The lower 
selection strength in infant IgM sequences at the pre-malaria timepoint is significantly 
higher during acute malaria infection (Figure 3.8a,d, CDR black curves between two 
timepoints, P < 0.0001 [numerical integration, as previously described25]), suggesting 
that the significant increase in SHM is antigen-driven and selected upon. In order to 
compare with a large amount of historical adult data, we calculated replacement to silent 
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mutation ratios (R/S ratios), which are about 2-3:1 in FWRs and 5:1 in CDRs for both 
infants and toddlers (Table B.5). These results are similar to adults24, 26, 27, 28 and much 
higher than what has been reported for children previously using a very limited number 
of sequences29. We also noticed that R/S ratio in the FWRs of IgM was much higher in 
infants, contrary to the BASELINe results, which highlights the importance of 
incorporating the expected replacement frequency when considering selection pressure. 
These results suggest that as an end result of interactions between antigen selection and 
SHM, the degree of antibody amino acid changes is comparable in infants, toddlers, and 
adults. It also suggests that cellular and molecular machineries for antigen selection are 




Figure 3.8: Antigen selection strength comparisons between infants and toddlers. 
Selection strength distributions, as determined by BASELINe25, were 
compared between infants (black) and toddlers (red) for PBMCs from pre-
malaria (a-c) (Ninfant=6, Ntoddler=9) and acute malaria (d-f) (Ninfant=6, 
Ntoddler=9) timepoints, separated by isotype: (a,d) IgM, (b,e) IgG, and (c,f) 
IgA. Selection strength on CDR (CDR1 and 2, top half of each panel) and 
FWR (FWR2 and 3, bottom half of each panel) for unique RNA molecules 
was calculated. CDR3 and FWR4 were omitted due to the difficulty in 
determining the germline sequence. FWR1 for all sequences was also 
omitted because it was not covered entirely by some of the primers. P value 
calculated as previously described25. 
3.2.6 Clonal lineages diversify upon acute febrile malaria 
The exhaustive sequencing data obtained by MIDCIRS offers the possibility to 
reconstruct clonal lineages that trace B cell development. Clonal lineages contain 
different species of unique antibody sequences that could be progenies derived from the 
same ancestral B cell. B cell clonal lineage analysis has been used to track affinity 
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maturation and sequence evolution of HIV broadly neutralizing antibodies30, 31. Using a 
clustering method with a pre-determined threshold (90% similarity on nucleotide 
sequence at CDR3), we previously demonstrated that B cell clonal lineages could be 
informatically defined and contain pathogen-specific antibody sequences7. In addition, 
the clonal lineage analysis also highlighted the lack of antibody diversification in the 
elderly after influenza vaccination7. Using the same approach and a similar threshold7, 32, 
we aimed to answer whether infants and toddlers are able to diversify antibody clonal 
lineages in response to infection and, if so, whether they have a similar ability to do so, 
which was previously impossible to answer due to technical limitations.  To do this, we 
first visualized structures of informatically defined clonal lineages for the entire antibody 
repertoire (Figure B.4). Each oval lineage map represents an individual PBMC sample at 
one timepoint. Densely packed individual lineages are not easily identified visually in 
Figure B.4; however, dark areas indicate that clonal lineages are already complex in this 
cohort of infants as young as 3 months old and can be further diversified upon acute 
febrile malaria.  
The densely packed lineages could result from large lineage sizes (one unique 
RNA molecule with many copies), large lineage diversities (many unique RNA 
molecules), or a combination of the two. To closely examine the possible differences in 
the degree of this intra-clonal lineage expansion and diversification between infants and 
toddlers, especially upon acute febrile malaria, we projected the global lineage structure 
(Figure B.4) onto diversity and size of lineage axes (Figure 3.9). Each circle represents 
an individual lineage, with the area of the circle proportional to the SHM load (average 
mutations of the lineage). This analysis effectively captures five parameters that quantify 
lineage complexity in a sample: number of total clonal lineages (number of circles), 
diversity of each lineage (x-axis position, number of unique RNA molecules in a 
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lineage), size of each lineage (y-axis position, number of total RNA molecules in a 
lineage), SHM load of each lineage (area of circle, key is located in between the infant 
and toddler panels in Figure 3.9), and the extent of clonal expansion of each lineage 
(distance from y=x parity line; no clonally expanded RNA molecules within a lineage if it 
is on parity line or pure clonal expanded RNA molecules if it is in the top left quadrant of 
each panel). 
Figure 3.10 shows two example lineages selected to display the full lineage 
structures to demonstrate a lineage with diversification and clonal expansion (Figure 
3.10a refers to green letter “a” indicated in Figure 3.9, Inf3) and another one with 
diversification but without clonal expansion (Figure 3.10b refers to green letter “b” 
indicated in Figure 3.9, Inf3). Both are represented by a single circle in Figure 3.9, but 
their locations in Figure 3.9 depend on the numbers of RNA molecules (y-axis) and 
numbers of unique RNA molecules (x-axis).  Lineage “b” (b in Figure 3.9, Inf3, zoomed 
in view in Figure 3.10b) that lies away from the origin and near the black y=x parity line 
consists of 8 unique sequences, each represented by only one RNA molecule, indicating 
extensive lineage diversification but no clonal expansion.  Lineage “a” (a in Figure 3.9, 
Inf3, zoomed in view in Figure 3.10a) that lies far from the parity line is dominated by 
two unique RNA molecules each with about 20 copies (Figure 3.10a, height of nodes), 
indicating extensive clonal expansion of particular sequences in addition to 
diversification. Changing lineage forming threshold from 90% to 95% does not change 





Figure 3.9: B cell lineage complexity change under malaria stimulation. Diversity and 
size of B cell lineages for infants (N=6) and toddlers (N=9) from whom 
paired PBMC samples at pre-malaria (blue) and acute malaria (pink) were 
obtained. Each circle represents an individual lineage. The area of each 
circle is proportional to the SHM load. Labeled green arrows indicate 
representative lineages whose intra-lineage structures were shown in detail 
in Figure 3.10. Each circle’s x and y coordinates were determined by its 
diversity (the number of unique RNA molecules in a lineage) and size (the 
number of total RNA molecules in a lineage), respectively. Blue and pink 
dashed lines represent the linear fit for pre- and acute malaria lineages, 
respectively. Black dashed lines indicate y=x parity, such that lineages lying 
on the parity line are comprised entirely of unique RNA molecules with 
minimum clonal expansion, such as lineage in Figure 3.10b. On the other 
hand, lineages comprised of clonally expanded RNA molecules are close to 
the y axis, such as lineage Figure 3.10a. 
This five-dimension lineage analysis reveals that infants as young as 3 months old 
can generate extensive lineage structures, with many lineages containing more than 20 
different types of antibody sequences and 50 RNA molecules (Figure 3.9). Toddlers have 
many more lineages with higher levels of both size and diversity. However, in both 
infants and toddlers, the majority of clonal lineages are singleton lineages consisting of 
only one RNA molecule (Figure 3.11a), consistent with the flow cytometry analysis that 
the bulk of the B cell repertoire is naive in these young children (Figure 3.7). Upon acute 
malaria infection, the fraction of non-singleton lineages increases in both infants and 
toddlers (Figure 3.11a). 
 51 
 
Figure 3.10: Visualized example lineages. (a) corresponds to green “a” labeled lineage in 
Figure 3.9. (b) corresponds to green “b” labeled lineage in Figure 3.9. Each 
node is a unique RNA molecule species. The height of the node corresponds 
to the number of RNA molecules of the same species, the color corresponds 
to number of nucleotide mutations, and the distance between nodes is 
proportional to the Levenshtein distance between the node sequences, as 
indicated in the legend above each lineage. All unlabeled nodes share the 
isotype with the root. 
In order to tease out whether these non-singleton lineages diversify or clonally 
expand upon acute infection, we fit linear regressions to the lineage diversity-size plots. 
An immune response against an infection can have a two-fold effect on the lineage 
landscape: antigen stimulation can cause clonal expansion, which would shift the lineage 
up on the y-axis, and SHM and affinity maturation, which would shift the lineage to the 
right on the x-axis. This balance between clonal expansion and diversification is depicted 
by the slope of the linear regression (Figure 3.9, dashed blue lines for pre-malaria 
samples and dashed pink lines for acute malaria samples). We hypothesized that the 
lower absolute SHM load of infants would imply a defect in the ability to diversify clonal 
lineages in response to infection, leading the slope change from pre-malaria to acute 
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malaria to be low (a small angle between blue and pink dashed lines) or even negative 
(pink dashed line is closer to y-axis than blue dashed line). Surprisingly, our analysis 
shows that infants diversify their clonal lineages in a similar manner as toddlers in 
response to acute malaria (Figure 3.11b). As singleton lineages do not bear any weight 
on the linear regression, our analysis shows that the increasing fraction of non-singleton 
lineages upon malaria infection is similarly diversified between infants and toddlers, 
which is also similar to a young adult at pre-malaria and acute malaria (Figure B.6). 
However, this sharply contrasts with what we had previously observed in the elderly 
following influenza vaccination, where clonal expansion dominated7. Among clonally 
expanding and diversifying B cell clones during an infection, only a subset of the cells 
comprising the clonal burst remain once the infection has been cleared. Thus, the 
characteristic change in the lineage size/diversity linear regression slope upon infection is 
expected to subside as time passes since the acute infection. Indeed, comparing the pre-
malaria lineage size/diversity linear regression slopes reveals no difference between 
infants (who have not experienced malaria before) and toddlers (who have experienced 
malarias in previous years) (Figure B.7). These results highlight the unexpected 
capability of young children’s antibody repertoire in response to a natural infection.  
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Figure 3.11: Infants and toddlers similarly diversify clonal lineages during acute malaria 
infection. (a) The non-singleton lineage percent (lineages comprised of at 
least 2 RNA molecules) between infants and toddlers at pre- (blue) and 
acute (pink) malaria.  *P < 0.05 by two-tailed Wilcoxon Signed-Rank test 
(between timepoints, solid lines); N.S. indicates no significant difference by 
two-tailed Mann-Whitney U test (between age groups, dashed lines). (b) 
The difference of linear regression slopes (angles) from Figure 3.9, or 
degree of diversity change, between pre- and acute malaria for infants 
(black) and toddlers (red). N.S. indicates no significant difference by two-
tailed Mann-Whitney U test. Bars indicate means. Differences in variance 
were not significant by squared ranks test. 
3.2.7 SHM load increases upon acute febrile malaria 
The plateau we observed on SHM load in toddlers at both pre- and acute malaria 
(Figure 3.5) and the lack of a SHM difference in IgG and IgA between pre- and acute 
malaria (Figure 3.6) seems to suggest that the experienced part of the repertoire does not 
respond to malaria infection by inducing SHM. However, it could be that only a portion 
of the bulk antibody repertoire responds to the infection and there is already a high level 
of baseline SHMs as revealed by the histogram analysis (Figure 3.4). Since we saw the 
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lineage diversification upon malaria infection in Figure 3.9, we hypothesized that 
examining the SHMs from sequences in two-timepoint-shared lineages (lineages 
containing both pre-malaria and acute malaria sequences) would enable us to quantify the 
infection-induced SHM increase from the highly mutated background. To test this, we 
pooled all sequences from both timepoints, including sorted memory B cells from the 
pre-malaria timepoint, and generated lineages again using the 90% similarity threshold at 
CDR37, 32. We are able to find two-timepoint-shared lineages in all individuals analyzed 
(Table B.6). Consistent with the observation that toddlers already have a diverse and 
expanded antibody repertoire compared to infants, there are more shared lineages in 
toddlers than infants (Table B.6). We tallied SHMs for sequences from pre-malaria and 
acute malaria in the two-timepoint-shared lineages separately. Consistent with our 
hypothesis, both infants and toddlers significantly increase SHM upon infection (Figure 
3.12a). Indeed, toddlers had a higher pre-malaria SHM level compared to infants (Figure 
3.12a, blue symbols). To our surprise, infants were able to induce more SHMs compared 
to toddlers (Figure 3.12b). These data suggested that indeed both infants and toddlers 




Figure 3.12: Two-timepoint-shared lineage analysis reveals SHM increment during acute 
malaria infection. (a) Average SHM for sequences from pre-malaria (blue) 
and acute malaria (pink) timepoints within lineages containing sequences 
from both timepoints for infants (N=6) and toddlers (N=9). ) *P < 0.05 by 
two-tailed Wilcoxon Signed-Rank test.  (b) Average SHM increase upon 
acute malaria infection for infants (black) and toddlers (red) from (a). *P < 
0.05 by two-tailed Mann-Whitney U test. 
3.2.8 Memory B cells further diversify upon malaria rechallenge 
The importance of IgM-expressing memory B cells has been reported in mice in 
several recent studies33, 34, 35, 36, including a mouse model of malaria infection37. 
However, fewer studies have examined these cells in humans21, and their composition 
and role in repertoire diversification upon rechallenge remains elusive. It is widely 
believed that they may retain the capacity to introduce further mutations and class 
switch33, 34, 37, 38. However, sequence-based clonal lineage evidence is lacking. The paired 
samples before and during acute malaria from toddlers who experienced malaria in 
previous years provided an opportunity to investigate the role of memory B cells in 
repertoire diversification upon rechallenge in children.  
 56 
Here, we focus on two-timepoint-shared lineages that harbor sequences from pre-
malaria memory B cells. Given the significant increase of SHM we identified at acute 
malaria sequences over pre-malaria sequences in two-timepoint-shared lineages (Figure 
3.12a), we reasoned that the high repertoire coverage of MIDCIRS should enable us to 
identify a large number of two-timepoint-shared lineages that contain these memory B 
cells, and these memory B cells should have mutated progenies at the acute malaria 
timepoint. To ensure that we identify sequence progenies of these pre-malaria memory B 
cells, we employed an antibody lineage structure construction algorithm, COLT, that we 
recently developed39. COLT considers isotype, sampling time, and SHM pattern when 
constructing an antibody lineage, which allows us to trace, at the sequence level, the 
acute progeny of these memory B cells. As illustrated by Figure 3.13, this COLT-
generated lineage tree depicts a pre-malaria memory B cell sequence serving as a parent 
node to sequences derived from the acute malaria timepoint. This analysis is much more 
stringent in identifying sequence progenies than simply judging if a pre-malaria memory 
B cell sequence is grouped with acute malaria PBMC sequences.  
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Figure 3.13: Multi-timepoint shared lineage example. Intra-lineage structure for a 
representative lineage from Figure 3.14. Blue dashed curve encompasses 
the pre-malaria timepoint derived sequence, and pink dashed curve 
encompasses the acute malaria timepoint derived sequences. Each node is a 
unique RNA molecule species. The height of the node corresponds to the 
number of RNA molecules of the same species, the color corresponds to the 
SHM load, and the distance between nodes is proportional to the 
Levenshtein distance between the node sequences, as indicated in the legend 





Figure 3.14: Flow diagram for two-timepoint-shared lineage containing pre-malaria 
memory B cell identification and acute progeny analysis. Percentages 
represent the average percent of unique sequences classified by the indicated 
slice, range in brackets. 
On average, 5% of unique sequences from 10,000 sorted memory B cells form 
lineages with acute malaria PBMC sequences (Figure 3.14, dark blue slice of the first 
pie). COLT39 analysis on these pre-malaria memory B cell-containing lineages shows that 
53% contain traceable progeny sequences from the acute malaria PBMCs (Figure 3.14, 
lighter blue slice of the second pie). Overall, there is a significant increase of SHM in 
these acute malaria progenies compared with their ancestor pre-malaria memory B cells 
(Figure 3.15a). Consistent with previous studies33, 34, 38, these progeny-bearing pre-
malaria memory B cells express all three major isotypes, with IgM being the dominant 
species (Figure 3.15b). Investigating their isotype switching capacity reveals that about 
60% of the IgM pre-malaria memory B cells maintain IgM as progenies; however, about 
20% only have isotype-switched progenies detected while the remaining 20% have both 
IgM and isotype switched progenies (Figure 3.15c). These pre-malaria IgM memory B 
cells largely retain IgM expression while further introducing SHM upon rechallenge. 
Thus, these analyses show multi-facet diversification potential of young children’s 
memory B cells in a natural infection rechallenge.  
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Figure 3.15: Memory B cells further mutate and class switch upon malaria rechallenge. 
(a) Average SHM load for pre-malaria memory B cells with acute progeny 
(blue) and their acute progenies (pink) for malaria-experienced toddlers with 
FACS sorted pre-malaria memory B cells (N=8). (b) Isotype distribution of 
pre-malaria memory B cells with acute progeny. (c) Isotype fate of acute 
progenies stemming from IgM pre-malaria memory B cells. Lines connect 
the same individuals. Bars indicate means. *P < 0.05, N.S. indicates not 
significant by two-tailed Wilcoxon Signed-Rank test. 
3.3 DISCUSSION 
About 13,000 children under one year old die every day worldwide40, and most of 
these deaths are caused by infection9. It has long been recognized that children’s immune 
systems are immature at birth and require time to develop to provide protection against 
pathogens or respond to vaccines. However, few studies have focused on children’s 
antibody repertoire development, diversification, and response to infection. Knowledge in 
this area holds great interest to vaccine development and vaccination strategy design. 
This is especially urgent for malaria, as it still kills about half a million children each 
year41, and the most advanced malaria vaccine confers only partial, short-lived protection 
in African children42. 
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However, studying the antibody repertoire in young children is challenging in 
several regards: first, lack of analytical tools to exhaustively study the antibody repertoire 
from small volumes of blood; second, lack of informatic analysis tools to turn high-
throughput data into knowledge; and third, the rarity of a set of samples from young 
children obtained before and at the time of a natural infection. To address these 
challenges, we developed a highly accurate and high-coverage immune repertoire 
sequencing tool, MIDCIRS, to analyze antibody repertoire development, diversification, 
and capacity to respond to a natural infection in children who were experiencing acute 
febrile malaria.  
Previous studies showed that there was evidence of SHM and antigen selection in 
infants 8 months of age or older by examining a few V gene alleles18.  However, it is not 
clear how widespread SHMs are in infant antibody repertoires and to what degree SHMs 
can be introduced in response to an infection. By using a comprehensive and unbiased 
analysis, here we show that infants as young as 3 months old can have 10% of sequences 
with 5 or more mutations, and they can further introduce mutations upon an acute febrile 
malaria infection to well over 20 SHM per 270nt heavy chain V region. Compared with 
toddlers, there is a separation on SHM load around 12 months: this number gradually 
increases before 12 months and stays at a plateau after that regardless of repeated malaria 
incidents. Consistent with this trend is the similar pattern observed in the increase in the 
percentage of memory B cells and corresponding decrease in percentage of naive B cells 
with age: both plateaued after 12 months of age. Accordantly, SHM load in IgM, IgG, 
and IgA correlates with the percentages of naive and memory B cells. Surprisingly, 
regardless of the lower mutation load in infants, their mutations are similarly, if not more 
strongly, selected as those of toddlers, suggesting that the molecular machineries and 
other cellular components involved in antibody selection are already developed in infants. 
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In future analyses, it will be of interest to tease out the mechanistic contributions to a 
two-stage increase of average mutation number, in particular the role of T cell help and 
germinal center formation. Regardless of these detailed mechanisms, it is clear infants 
can perform antibody selection as well as toddlers and adults, which provides some 
assurance of the effectiveness of vaccination in young children.  
Another interesting finding is that infant antibody repertoires are capable of 
diversification, as seen through the clonal lineage analysis. We show that both infants and 
toddlers diversify their repertoire to the same degree upon an acute febrile malaria 
infection. Although adults have a larger range on the diversity of the lineage because they 
have accumulated more mutations, the degree of repertoire diversification in infants and 
toddlers is similar to what adults experience at an acute febrile malaria. This contrasts 
how elderly individuals preferentially increase the size of these lineages due to clonal 
expansion after influenza vaccination7. Together, these data provide evidence that infant 
antibody repertoires are similarly capable of responding to malaria as toddlers and adults.  
Analyzing antibody lineages formed by sequences from both pre-malaria and 
acute malaria samples, we see an increase in SHM upon malaria infection. While the high 
background SHMs at pre-malaria prevented us from detecting an increase of SHM upon 
malaria infection in the bulk repertoire except in IgM, our two-timepoint-shared lineage 
analysis shows both infants and toddlers increase SHMs upon acute malaria infection. 
This highlights the power of combining informatics analysis with improved technology – 
the magnitude of SHM increase in toddlers is relatively small compared with infants, 
which would have been missed if MIDs were not used. Similar problems may prevent a 
recent study from identifying an increase of SHM in healthy adults who received 
influenza vaccination21. It is also possible that the perturbation of a natural infection is 
much stronger than vaccination. The evidence we observe that infants have a similar 
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propensity to diversify clonal lineages, perform antigen selection, and increase SHM load 
in acute malaria also provides a comprehensive assessment of the capacity of infants’ 
antibody repertoire to respond to a natural infection. These results also provide some 
assurance that infants are capable of responding to external stimuli and develop 
significantly diversified antibody lineages. These, along with the observation that 
administering anti-parasite drugs in the first 10 months of life correlated with higher 
malaria incidence in second year of life43, suggest that repeated vaccination might mimic 
the naturally acquired clinical malaria resistance that arises through repeated malaria 
exposures12, 43. 
Using progeny tracing in two-timepoint-shared lineages containing pre-malaria 
memory B cells, we were able to detect total of 1799 lineages that contained acute 
progenies. We analyzed conventional memory B cells because the atypical memory B 
cell frequency is low in this cohort of young children (Figure B.8). This is possibly due 
to the relatively few malaria incidents in these young children, as opposed to adults and 
older children that we and others have analyzed where atypical memory B cell increases 
prevalence as a result of many years of chronic malaria exposure44, 45. In depth analysis 
shows both continued SHM and isotype switching in memory B cells in response to a 
natural infection rechallenge. Although we do not know the cell phenotype of these 
progeny sequences, it is reasonable to speculate that some of them could have developed 
into plasmablasts. A previous study has shown that plasmablasts have about 30 to 35 
times more transcripts per cell compared to other peripheral B cell populations46. Even 
when we relaxed the threshold and counted all unique sequences that had more than 10 
copies as plasmablasts, at most 2.1% of unique sequences in these pre-malaria memory B 
cell-derived progenies could be inferred as plasmablasts (Figure B.9). Applying the same 
threshold to bulk PBMC sequences from acute malaria timepoint resulted in a similar 
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percentage of plasmablasts-derived sequences, which is consistent with about 2.2% of 
plasmablasts by flow cytometry analysis. All together, these data suggest that most of the 
progenies from pre-malaria memory B cells remain memory B cells and continued to 
increase SHMs in these young children. 
In summary, we developed an improved method of utilizing MIDs to significantly 
enhance the coverage and dynamic range of IR-seq. Using it, we systemically studied the 
antibody repertoire in malaria-exposed infants and toddlers and discovered several 
aspects of repertoire development, diversification, and capacity to respond to an infection 
that were not known before, which provides not only new parameters and approaches in 
quantifying vaccine efficacy beyond traditional serological titer but also venues for future 
studies of detailed molecular and cellular mechanisms that drive antibody repertoire 
differences between infants and toddlers.   
3.4 METHODS 
3.4.1 Study design and cohort 
Infant and toddler PBMC samples from 22 residents of Kalifabougou, Mali, 
ranging from 3 months old to 47 months old, were collected from an ongoing malaria 
cohort study12 and analyzed as summarized in Table B.1.  Enrollment exclusion criteria 
were hemoglobin level <7 g/dL, axillary temperature ≥37.5°C, acute systemic illness, use 
of antimalarial or immunosuppressive medications in the past 30 days, and pregnancy. 
The research definition of malaria was an axillary temperature of ≥37.5°C, ≥2500 asexual 
parasites/µL of blood, and no other cause of fever discernible by physical exam. The 
Ethics Committee of the Faculty of Medicine, Pharmacy, and Dentistry at the University 
of Sciences, Technique, and Technology of Bamako, and the Institutional Review Board 
of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, 
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approved the malaria study, from which we obtained frozen PBMCs. Written informed 
consent was obtained from adult participants and from the parents or guardians of 
participating children. The study is registered in the ClinicalTrials.gov database 
(NCT01322581). 
For this study, individuals were chosen based on the availability of frozen PBMCs 
in the age range specified.  Blood draws were taken before the rainy season, when 
mosquitos are not rampant and the cases of malaria are low, and during acute febrile 
malaria (Figure 3.1). Samples were labeled for analysis by the group (Inf/Tod), patient 
ID, timepoint, and age at blood draw (in months), e.g. Inf1-Pre3m represents the pre-
malaria timepoint for infant 1 who was 3 months  old at the time of blood draw (Table 
B.1). Samples collected before the beginning of the rainy season that tested PCR negative 
for Plasmodium falciparum and Plasmodium malariae were designated “pre-malaria”. 
Samples collected 7 days into acute febrile malaria infection were designated “acute 
malaria”.  Among them, 2 individuals were tracked for 2 consecutive malaria seasons and 
only the pre-malaria timepoint was obtained and analyzed for 9 individuals around the 
infant to toddler transition, as indicated in Table B.1. Authors were not blinded to the age 
group allocation or to the sample collection time. 
3.4.2 Cell sorting 
Frozen PBMCs were thawed, washed once in RPMI, and then processed for cell 
staining and sorting following standard FACS staining protocol47, 48. Up to 5,000,000 
PBMCs were lysed directly.  The remaining PBMCs were analyzed via flow cytometry; 
plasmablasts were gated based on the phenotype of CD4-CD8-CD14-CD56-
CD19+CD27brightCD38bright, memory B cells were gated based on the phenotype of CD4-
CD8-CD14-CD56-CD19+CD20+CD27+CD38low, and naive B cells were gated based on 
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the phenotype of CD4-CD8-CD14-CD56-CD19+CD20+CD27–CD38low. Naive and 
memory B cells were not gated on IgD or CD21, so only conventional memory B cells 
were analyzed. Sorted cells were lysed in RLT Plus buffer (Qiagen) supplemented with 
1% β-mercaptoethanol (Sigma).  The following antibody clones were obtained from 
Biolegend and used as 1:25 dilution: Alexa Fluor 488 OKT3 (CD3), Alexa Fluor 700 
RPA-T4 (CD4), Alexa Fluor 488 HCD14 (CD14), APC-Cy7 2H7 (CD20), PE-Cy7 O323 
(CD27), APC HIT2 (CD38), Alexa Fluor 488 MEM-188 (CD56), and Brilliant Violet 
605 IA6-2 (IgD). The following antibody clones were obtained from BD Biosciences: 
PE-CF594 RPA-T8 (CD8), Brilliant Ultraviolet 395 SJ25C1 (CD19), and Brilliant 
Ultraviolet 737 B-ly4 (CD21). Flow cytometry and cell sorting were performed on BD 
FACS Aria II. 
3.4.3 Bulk antibody sequencing and reads processing 
Antibody sequencing libraries were prepared and processed as described in 
Chapter 2: Methods 2.4.2-4.  
3.4.4 VDJ definition and mutation counts 
As described in previous work, similar methods were used to define the V, D, and 
J gene segments for all sequences7, 13, 49. From the International ImMunoGeneTics 
information system database (IMGT, http://www.imgt.org/textes/vquest/refseqh.html)50, 
human heavy chain variable gene segment sequences (249 V-exon, 37 D-exon and 13 J-
exon) were downloaded. Each unique sequence was first aligned to all 249 V gene 
alleles. The specific V-allele with a maximum Smith-Waterman score was then assigned. 
In some cases, newly identified germline alleles, defined either by TIgGER23 or our 
method (below), were added to the template sequences. J-segments and D-segments were 
then similarly assigned. The number of mutations from germline sequence was counted 
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as the number of substitutions from the best aligned V and J templates as previously 
described7, 13, 49. The CDR3 was omitted due to the difficulty in determining the germline 
sequence. The germline sequences of V, D, and J gene segments were grouped by 
combining similar alleles into families using IMGT designation in VDJ correlation plots. 
In total, 58 V, 27 D, and 6 J families were used. 
3.4.5 Novel allele detection 
To address the possibility of novel germline alleles inflating the observed number 
of mutations, new germline alleles were assembled.  See Chapter 4 Methods 4.4.2 for 
detailed methodology for novel allele detection. TIgGER was used as previously reported 
as another method to discover novel alleles23. TIgGER compares the mutation rate at a 
specific position to the overall number of mutations for sequences within the same 
assigned V-gene allele.  Outliers within the low mutation region suggests the existence of 
a novel allele, and the shape of the curve can effectively distinguish between individuals 
homozygous and heterozygous for the novel allele.   
Our new method and TIgGER have a 90% percent overlap in newly identified 
alleles.  Discrepancies between the two methods were treated with a conservative 
estimation on the number of SHM, meaning we liberally included novel alleles as part of 
the germline gene segments.  Non-overlapping novel alleles were manually inspected, 
and the union of novel alleles detected by TIgGER and our method was included as part 
of the germline gene segments. Sequences mapped to these novel alleles were excluded 
from our analysis, which accounts for an average 8% of all sequences (Table B.3). 
3.4.6 Translation from nucleotide to amino acid sequences 
Nucleotide sequences were translated into amino acid sequences based on codon 
translation as previously described7, 13, 49. The unique RNA sequences were inputted to 
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IMGT High V quest to translate into amino acid sequences. The boundary of the CDR3 is 
defined by IMGT numbering for Ig and two conserved sequence markers of ‘Tyr-
(Tyr/Phe)-Cys’ to ‘Trp-Gly.’ CDR3 length was determined according to these anchor 
residues. 
3.4.7 Selection pressure 
The selection pressure was evaluated via BASELINe25. The unique RNA 
molecules of PBMC, populations were inputted to BASELINe and compared with the 
closest IMGT germline alleles. The observed number of replacement and silent mutations 
were compared with the expected number of mutations for the assigned germline 
sequence. A selection strength as measured by the probability density function (PDF) was 
generated using BASELINe to indicate the direction and degree for CDR (CDR1 and 2) 
and FWR (FWR2, and 3) regions for each unique RNA molecule first, then combined for 
each individual, and then further combined for each of the two groups, infants and 
toddlers. The PDFs were plotted and compared between infants and toddlers (Figure 
3.8). The associated P values comparing two group PDFs were calculated using a 
numerical integration approach that is part of the BASELINe package. Samples with 
5,000,000 PBMCs were subsampled to 120,000 RNA molecules. Samples with fewer 
PBMCs were subsampled to proportionally fewer RNA molecules according to the 
PBMC number. 
3.4.8 Replacement/silent mutations 
According to the amino acid sequence translation results and V/D/J gene 
templates alignment results, we counted the number of nucleotide mutations resulting in 
amino acid substitutions (replacement, R) or no amino acid substitutions (silent, S) in 
FWR region (FWR2 and  3) and CDR region (CDR1 and 2) using the IMGT/HighV-
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QUEST51. The number of silent and replacement mutations was averaged in each age-
group (Infant and Toddler) and the ratio for silent vs. replacement mutation was 
calculated. The CDR3 and FWR4 were omitted due to the difficulty in determining the 
germline sequence. FWR1 for all sequences was also omitted because it was not covered 
entirely by some of the primers. Samples with 5,000,000 PBMCs were subsampled to 
120,000 RNA molecules. Samples with fewer PBMCs were subsampled to proportionally 
fewer RNA molecules according to the PBMC number. 
3.4.9 VDJ usage correlation 
The correlation of VDJ usage between infants and toddlers were calculated with 











  (3.1) 
 
𝑣𝑑𝑗 refers to the combination of one 𝑣 allele family from 58 V gene allele 
families ({𝑉}), one 𝑑 allele family from 27 D gene allele families ({𝐷}), and one 𝑗 allele 
family from 6 J gene allele families ({𝐽}). For the reads weighted correlation, 𝑋𝑣𝑑𝑗 and 
𝑌𝑣𝑑𝑗 refer to the fraction of reads assigned to the respective 𝑣𝑑𝑗 combination for 
individuals 𝑋 and 𝑌, respectively. < 𝑋 > and < 𝑌 > are the average reads across all 𝑣𝑑𝑗 
combinations. For the lineage weighted correlation, these parameters refer to the fraction 
of lineages for each 𝑣𝑑𝑗 allele family combination.  Samples with 5,000,000 PBMCs 
were subsampled to 120,000 RNA molecules. Samples with fewer PBMCs were 
subsampled to proportionally fewer RNA molecules according to the PBMC number. 𝑣𝑑𝑗 
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combinations that were not detected in either sample being compared were omitted from 
the correlation calculation. 
3.4.10 Clustering sequencing into clonal lineages 
Sequences with similar CDR3 are possibly progenies from the same naive B cell 
and can be grouped into a clonal lineage. To detect the lineage structure for the antibody 
repertoire, we performed single linkage clustering, using a re-parameterization of the 
method described previously7, 13, 32, accounting for the larger size of the CDR3 and 
junction in humans as compared to zebrafish. RNA sequences with the same V and J 
allele assignments, the same junction length, and whose junction regions differed by no 
more than 10% on the nucleotide level were grouped together into a lineage. This is 
equivalent to a biological clone that underwent clonal expansion. In order to test the 
robustness of this threshold, we also tried the threshold of 95% similarity for CDR3 
region32, and it did not change the overall position of each lineage in the diversity-size 
plot, nor did it change the linear fits of lineage distribution generated from these two 
threshold (Figure B.5). Lineage diversity is the number of unique RNA molecules within 
the lineage, and lineage size is the total number of RNA molecules within the lineage. 
Samples with 5,000,000 PBMCs were subsampled to 120,000 RNA molecules. Samples 
with fewer PBMCs were subsampled to proportionally fewer RNA molecules according 
to the PBMC number. 
3.4.11 Clonal lineage diversification 
In order to discuss the clonal lineage diversification, the size and diversity, as 
described above, were plotted against each other for pre- and acute malaria time points 
for each individual (Figure 3.9). The linear regression visualizes the average degree of 
diversification relative to clonal expansion. A characteristic shift towards further 
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diversification of clonal lineages upon acute malaria infection was evaluated by the 
decrease in the slope of the linear regression for each infant and toddler.  The shift was 
calculated by the difference between the arctangents of the slopes of the linear 
regressions. 
3.4.12 Two-timepoint-shared lineage analysis 
To test the effects of acute malaria infection on the structure of clonal lineages, 
RNA molecules from both the pre- and acute malaria timepoints were grouped together 
and subjected to clustering into clonal lineages as described above. Resulting lineages 
that contained sequences from both the pre-malaria and acute malaria timepoints were 
isolated for mutational analysis. Within these shared lineages, the average number of 
mutations for the pre-malaria sequences was calculated alongside the average number of 
mutations for the acute malaria sequences (Figure 3.12).  
3.4.13 Lineage structure visualization 
Representative lineages were selected to visualize the lineage structures and the 
evolution of antibody sequences. Lineage structures were generated using COLT39 
(software can be downloaded here: 
http://www.cs.wright.edu/~keke.chen/software/colt.zip) and validated manually. We 
implemented a lineage visualization tool, COLT-Viz (He et al., submitted). In short, 
COLT considers constraints (e.g. isotype and timepoint) along with mutational patterns to 
build lineage trees. The height of each node is proportional to the number of RNA 
molecules associated with the unique sequence (size), the color of each node relates to 
the number of SHMs, and the distance between nodes is proportional to the Levenshtein 
distance between the node sequences. 
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3.4.14 Pre-malaria memory B cells with acute progeny lineage analysis 
To determine the fate of the pre-malaria memory B cells upon acute malaria 
infection, two-timepoint-shared lineages were formed as described above, and lineages 
containing sequences from both FACS-sorted pre-malaria memory B cells and acute 
malaria PBMCs were isolated for further analysis. COLT was used to generate lineage 
tree structures. Pre-malaria memory B cells that served as parent nodes to acute malaria 
sequences, as exemplified (Figure 3.13), were considered “pre-malaria memory B cells 
with acute progeny”.  
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Chapter 4: A streamlined approach to antibody novel germline allele 
prediction and validation3 
4.1 INTRODUCTION 
V(D)J recombination and non-template nucleotide insertion in the junction 
regions generate the first level of antibody repertoire diversity. During an immune 
response, B cells that are activated by binding their matching antigens go through a 
clonal expansion process accompanied by somatic hypermutations (SHMs) that are quasi-
randomly introduced to the antibody genes. These mutated antibodies are then selected 
based on binding strength to the antigen, leading to a second generation of higher affinity 
antibodies1, 2, 3. 
Antibody repertoire SHM patterns have been implicated in a wide range of 
applications, from the development of broadly neutralizing antibodies against HIV to the 
diminished effectiveness of vaccines in elderly subjects4, 5, 6. The recent incorporation of 
molecular barcodes into high-throughput immune repertoire sequencing has improved the 
ability to discern individual SHMs from PCR and sequencing errors7, 8; however, accurate 
SHM calling requires an accurate set of reference germline sequences to align to. The 
polygenic and polyallelic nature of the variable domain locus confounds this issue. 
Currently, 259 functional human antibody heavy chain V gene alleles listed in the IMGT 
database can be broken into 7 subfamilies that likely share common evolutionary 
ancestors based on sequence similarity9, but recent studies have shown that individuals 
often carry novel alleles that have yet to be characterized in the IMGT database10, 11, 12. 
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These novel alleles can be problematic for antibody repertoire analysis because single 
nucleotide polymorphisms (SNPs) between the novel alleles and the nearest IMGT alleles 
will instead be counted as SHMs on every sequence utilizing that allele, inflating the 
SHM load and skewing the SHM patterns. Although there are several software tools10, 11 
to predict the existence of novel alleles, a simple method for novel allele prediction and 
validation is lacking, especially using a small amount of blood samples.    
Here, we report a streamlined method for predicting novel alleles from bulk 
antibody repertoire data and validating them by sequencing unrecombined genomic DNA 
(gDNA) from FACS-sorted non-B cells. This method can be applied to PBMCs and B 
cells purified from as little as 4ml of blood. 6 novel alleles across 8 different subjects 
from a larger, ongoing malaria study cohort13 were predicted and validated with perfect 
congruency between the expressed repertoire and gDNA. This method can quickly and 
easily be applied to any antibody repertoire data to mitigate the effects of germline 
mismatches on SHM patterns.  
4.2 RESULTS 
4.2.1 Bulk antibody repertoire novel allele prediction 
Antibody repertoire sequencing data from bulk PBMCs were collected and 
processed as described in Methods 4.4.2 and summarized in Figure 4.1. IgM sequences 
were used to calculate the mutation distribution by position because IgM is mostly 
expressed on naïve B cells that have not been activated and have fewer SHMs compared 
to other isotypes. As expected, the percentage of unique sequences mutated at each 
position in IgM is low, even for SHM hotspots (Figure 4.2a). However, a large spike at 
one (or more) specific position(s) could indicate the presence of a novel allele resulted 
from SNP(s) (Figure 4.2b).  
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A threshold of 20% of unique sequences harboring the identical predicted SNP(s) 
was applied to determine a positive hit on novel allele (Figure 4.2, dashed horizontal 
line). Several IGHV genes, e.g. IGHV1-69 and IGHV3-30, have copy-number variants 
(CNVs) that arose from chromosomal segmental duplication and insertion/deletion 
events, leading to a diploid copy number ranging from 0 to 4 alleles present for a given 
gene for an individual14, 15. For genes with up to 4 copies, this 20% threshold can account 
for a heterozygous genotype with 1 of 4 copies being the novel allele, which should 
roughly have a 25:75 split on the usage of these four alleles. 6 genes with predicted novel 
alleles were chosen for validation (Table 4.1, column headers). These novel alleles were 
also predicted independently using TIgGER10, another novel germline allele detection 




Figure 4.1: Overview of novel allele prediction schematic from bulk repertoire 
sequencing data. Color indicates best-matched IMGT reference germline 




Figure 4.2: Novel germline allele prediction from bulk repertoire sequencing data. 
Representative percent of unique IgM sequences mutated for each position 
along the sequence for the absence (a) and presence (b) of a novel allele 
resulted from SNP(s). Color indicates the nucleotide substitution: A (blue), 
C (pink), G (black), and T (red).  * indicates SHM hotspots; dashed line 
indicates prediction threshold of SNP calling; x indicates SNP on predicted 
novel allele compared to the closest IMGT reference germline allele. SNP is 

















1 +/+ +/+ +/+* -/- +/+ -/- 
2 -/N.D. -/- -/- +/+ -/- -/-$ 
3 -/- +/+* -/- -/- +/+ +/+ 
4 +/+ -/- -/-* -/- -/- -/- 
5 -/- -/- -/- +/+ -/- -/- 
6 +/+ -/-* +/+ -/-$ +/+ -/-$ 
7 +/+ -/- +/+* -/-$ -/- -/- 
8 +/+ +/+ -/- -/-$ -/- -/- 
Table 4.1: Summary of gDNA validation of novel alleles predicted by bulk repertoire 
sequencing data. +/+ (dark green) indicates positive in both the bulk 
repertoire and the gDNA data for predicted SNPs; -/- (light green) indicates 
negative in both the bulk repertoire and the gDNA data for predicted SNPs; 
-/N.D. (yellow) indicates negative in bulk repertoire data but gDNA failed to 
amplify during gDNA validation for predicted SNPs. * indicates the 
existence of CNVs with more than 2 alleles detected in the gDNA data that 
belong to the same gene. $ indicates the gene was not detected in the 
repertoire or gDNA, possibly due to gene deletion. 
4.2.2 gDNA novel allele validation 
gDNA purified from FACS-sorted T cells from the same 8 subjects was used to 
validate the presence of the predicted novel alleles as described in Methods 4.4.3 and 
summarized in Figure 4.3. Due to the high degree of sequence homology among the V 
genes, a series of filtering steps was applied to eliminate reads that were distant from the 
putative novel allele or closest IMGT allele. Finally, the number of reads exactly 
matching the novel and original IMGT sequences were compared. If 20% of these reads 
matched the novel allele sequence, the subject was deemed positive for the novel allele. 
All 17 of the positive hits from the bulk repertoire data returned positive hits from the 
gDNA, and 30 out of 31 negative hits from the bulk repertoire data that were tested in 
parallel were also negative in the gDNA, with one library failing to amplify (Table 4.1).  
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Figure 4.3: Novel allele validation by targeted gDNA sequencing. (a) Overview of 
targeted gDNA amplification and library preparation. x indicates predicted 
SNP on novel allele compared to the closest IMGT reference germline 
allele. (b) Overview of gDNA sequencing data analysis for the presence 
(left) and absence (right) of a novel allele resulted from SNP(s). Color 
indicates best-matched IMGT reference germline allele assignment; x 
indicates SNP to the closest IMGT reference germline allele. 
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The positive hits in the bulk repertoire data ranged from 22.7% - 99.9% of unique 
sequences containing the novel mutation, while the negative hits ranged from 0.0% - 
1.6% (Figure 4.4, x-axis). This tight range on the negative hits is consistent with the low 
rate of mutations expected for IgM antibodies. For the gDNA validation, the positive hits 
ranged from 29.0% - 100% of filtered reads exactly matching the novel sequence, while 
the negative hits all failed to detect a single novel allele read (Figure 4.4, y-axis). The 
densely packed clusters at the bottom left and top right of Figure 4.4 imply that this 
method is sensitive enough to distinguish between heterozygous and homozygous 
genotypes, and our threshold of calling a novel allele on both gDNA and repertoire data, 
which is 20% of reads mapped to either putative allele or its closest IMGT allele, is 
appropriate. 
Another observation that increases confidence in novel germline allele prediction 
is the detection of the identical novel allele in multiple individuals11. 5 of the 6 alleles 
tested were positively validated in 2 or more subjects (Table 4.1). The lone allele 
detected in a single individual, IGHV4-61*01 (C93T_C136G_A138C), is 3 mismatches 
away from the nearest IMGT germline allele. None of the gDNA reads for this individual 
matched the reference allele, while all of the filtered reads exactly matched the predicted 
novel sequence. Additionally, none of the filtered reads from all 7 negative subjects 
tested in parallel matched the novel sequence.  
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Figure 4.4: Novel germline allele prediction and validation congruency. Correlation 
between the percentage of novel allele sequences in bulk IgM repertoire data 
(%) and the percentage of novel allele sequences in gDNA data (%). Most 
points are clustered at the origin (N = 30) or the top right (N = 9). Black 
dotted line represents the linear regression; red dashed lines indicate the 
novel allele calling threshold. 
4.3 DISCUSSION 
We developed a remarkably sensitive yet simple method for detecting and 
validating novel alleles from bulk antibody repertoire sequencing data. This approach 
requires little specialized bioinformatics analysis and no unique laboratory equipment or 
reagents. gDNA validation can be performed on DNA purified from as few as 2,000 
FACS-sorted non-B cells, maximizing the proportion of the sample that can be utilized 
for antibody repertoire analysis.  
The combination of antibody repertoire and non-B cell gDNA sequencing allowed 
for advanced insight into the genotypes of the subjects. Novel allele IGHV1-69*01 
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(G163A) was found to be an exact match with IMGT allele IGHV1-69*07, except 
IGHV1-69*07 is truncated at both ends. After performing nested PCR, these alleles were 
indistinguishable. However, in the 3 subjects predicted to have the novel allele, no unique 
sequences in the bulk repertoire data mapped to the truncated IGHV1-69*07 allele; 
instead, they contained the full length IGHV1-69*01 sequence with the G163A SNP. 
IGHV1-69 and IGHV1-69D share common alleles that can range from 2 to 4 
copies total on a diploid genome, and IGHV3-30 and IGHV3-30-5 share common alleles 
that can range from 0 to 4 copies total on a diploid genome15. Interestingly, we detected 
more than 2 alleles in the gDNA of 2 of 8 subjects for IGHV1-69/1-69D, consistent with 
previous studies on IGHV1-69 CNV in African populations14, and more than 2 IGHV3-
30/3-30-5 alleles were detected in 3 of 8 subjects (* in Table 4.1). Conversely, IGHV4-
31 and IGHV4-61 are associated with deletion events yielding 0 to 4 copies, each15. 
IGHV4-31 was not observed in the repertoire or gDNA of 3 of 8 subjects, and IGHV4-61 
was not observed in the repertoire or gDNA of 2 of 8 subjects ($ in Table 4.1), likely 
indicating the absence of these genes in these subjects.  These results demonstrated the 
sensitivity of our approach and emphasized the necessity of characterizing individual’s 
own germline alleles in antibody repertoire sequencing studies in order to accurately 
count number of SHMs.  
The results were highly consistent with all 17 predicted positive hits and 30 of 31 
predicted negative hits confirmed in gDNA. One limitation is that this method will only 
detect novel alleles that are similar to alleles within the IMGT reference database. 
Additionally, if a CNV results in more than 4 alleles present in the diploid genome for a 
given gene in an individual, then our threshold of a putative SNP call, which is least 20% 
of unique IgM sequences having the same mismatch at the same position, would not be 
able to detect the novel allele initially in the antibody repertoire data. However, this is 
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extremely rare based on current knowledge of antibody gene loci15. In summary, at least 
1 novel allele was found in each subject tested, highlighting the need for novel allele 
detection and correction in antibody repertoire analysis.  
4.4 METHODS 
4.4.1 Study design and cohort 
PBMC samples from 8 residents of Kalifabougou, Mali were collected from an 
ongoing malaria cohort study13. Up to 5 million PBMCs were directly lysed for antibody 
repertoire sequencing, and T cells were FACS-sorted from the remaining PBMCs for 
unrecombined gDNA validation. 6 predicted novel alleles were chosen for validation. 
The Ethics Committee of the Faculty of Medicine, Pharmacy, and Dentistry at the 
University of Sciences, Technique, and Technology of Bamako, and the Institutional 
Review Board of the National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, approved the malaria study, from which we obtained frozen PBMCs. 
Written informed consent was obtained from adult participants and from the parents or 
guardians of participating children. The study is registered in the ClinicalTrials.gov 
database (NCT01322581). 
4.4.2 Antibody repertoire sequencing and novel allele prediction 
Antibody repertoire sequencing was performed as described in Chapter 2 
Methods 2.4.2-4. Novel allele prediction schematic is summarized in Figure 4.1. In 
short, unique IgM sequences from bulk PBMC samples were used to minimize the effects 
of SHM and clonal expansion, as they are more likely to be derived from naïve B cells 
and thus have fewer SHMs than other antibody isotypes.  These sequences were first 
aligned to the reference germline allele database (e.g. IMGT) and assigned to the best-
matched alleles. The ratios of perfectly matched sequences to those with 1, 2, 3 and 4 
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mismatches (putative SNPs) compared to the reference germline were determined. Ratios 
of less than 2 to 1 were then inspected for identical mutation patterns. If identical 
mutations were present in at least 20% of the unique sequences, with less than 2% of the 
sequences harboring different mutations at the same positions, the allele containing those 
SNPs was flagged as a possible novel allele. 
4.4.3 gDNA sequencing and reads processing 
Nested PCR was used to reduce nonspecific amplification. Primers were designed 
such that the inner primers were no fewer than 14 bases away from the locations of the 
predicted IMGT/novel allele mismatches. Inner primers were fused to partial Illumina 
adaptors, and a third PCR was performed to add the full adaptor sequence (Table C.1). 
1st PCR was performed on 10% of purified gDNA from 2,000 sorted T cells using 
Phusion Hot Start II DNA Polymerase (Thermo Scientific) with the following protocol: 
98 ⁰C for 1 minute; 10 cycles of 98 ⁰C for 30 seconds, 57 ⁰C for 1 minute, and 72 ⁰C for 
5 minutes; then 72 ⁰C for 10 minutes. 2nd PCR was performed on 10% of the 1st PCR 
product with the same protocol. Final adaptor ligation was performed on 10% of the 2nd 
PCR product using TaKaRa Ex Taq DNA Polymerase Hot Start with the following 
protocol: 95 ⁰C for 3 minutes; 10 cycles of 95 ⁰C for 30 seconds, 57 ⁰C for 30 seconds, 
and 72 ⁰C for 2 minutes; then 72 ⁰C for 7 minutes. Libraries were pooled, gel-purified, 
and sequenced via Miseq 2x250 PE. 
Sequencing reads were first merged using the SeqPrep tool 
((https://github.com/jstjohn/SeqPrep). IgBlast16 was then used to align the reads to the 
established IMGT germline allele database. Reads mapping to the nearest germline allele 
to the novel allele of interested were filtered. Reads matching exactly to the IMGT 
germline allele or the novel allele sequence were tallied. If the exact novel allele 
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sequence was found in 20% or more of the tallied reads, the sample was considered a 
positive hit.  
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Chapter 5: HIV-driven T cell expansion promotes restricted functional 
diversity in germinal center follicular helper T cells4 
5.1 INTRODUCTION 
Follicular helper T cells (TFH) are a subset of CD4
+ T cells within secondary 
lymphoid organs that provide key signals necessary for B cell survival, maturation, and 
antibody production1, 2. In particular, CD57 expression on TFH cells marks a TFH cell 
subset that localizes to the germinal center (GC) and is required for isotype switching, 
somatic hypermutation, and the selection of high affinity B cell clones3, 4.  During chronic 
HIV infection, GC TFH cells become a primary target of HIV infection. Studies of lymph 
nodes (LN) from untreated HIV+ patients have detected substantial enrichment of p24 
antigen expression predominantly in GC and up to 10-fold higher frequency of HIV 
proviral DNA containing cells within the CD57+ subset compared to other CD4+ T cells5, 
6.  Thus, GC TFH cells play a crucial role in lymphoid biology and are also a major HIV 
reservoir contributing to viral persistence during chronic HIV infection.  
Paradoxically, while the frequency of TFH cells and serum immunoglobulin 
become elevated during chronic HIV infection, HIV+ patients develop a less efficient 
antibody response to immunization7, 8.  For example, HIV-infected patients produce 
lower titers of antibodies and less durable responses to seasonal influenza vaccines9, 10, 11.  
Cubas et al. used TFH cells from HIV
+ LNs to show that PD-L1 expression on B cells 
dampens TFH cell function
12.  We hypothesize that GC TFH cells are themselves targeted 
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by HIV-mediated changes and acquire new functional and phenotypic characteristics. In 
addition, as antigen-dependence of GC TFH cell expansion in HIV
+ LNs has never been 
evaluated, it remains unclear whether the increase in GC TFH cells results from an 
antigen-driven process or reflects general immune activation during chronic HIV 
infection.  
Recent breakthroughs in single cell-based protein expression analysis have led to 
a better appreciation of the complexity of cell populations in different tissue 
compartments.   At the forefront of these new analysis tools is mass cytometry (CyTOF), 
which combines the advantages of flow cytometry with mass spectrometry to measure 
protein expression by the detection of heavy metal isotope-specific signatures produced 
by cells stained with metal ion-conjugated antibodies13.  Here, we applied CyTOF to 
analyze the cellular diversity of GC TFH cells and combined this approach with T cell 
receptor (TCR) repertoire sequencing to trace the clonal composition of GC TFH cells 
during chronic viral infection.  We hypothesize that chronic viral stimulation drives a 
reduction in TFH cell diversity via preferential expansion of an activated and functionally 
distinct subset of GC TFH cells.  Using a unique set of LN samples obtained from HIV
+ 
patients, healthy controls (HCs), and patients with active inflammatory bowel disease 
(IBD), our data revealed HIV-specific skewing in the functional and activation states of 
GC TFH cells. We also found evidence of antigen-driven convergent selection and 
expansion of these GC TFH cells under chronic viral stimulation. These data provide an 
in-depth analysis of HIV-induced perturbation on GC TFH cells and emphasize a key role 
for HIV infection in driving GC TFH cell pathology.  
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5.2 RESULTS 
5.2.1 GC TFH cells are elevated in HIV+ patients and acquire distinct characteristics 
during chronic inflammation  
To evaluate the cellular diversity of GC TFH cells, we designed a mass cytometry 
panel to examine phenotypic and functional features of TFH cells (Table D.1).  LN 
samples were obtained from 25 HIV+ patients, including 20 who were treatment naïve 
(Table D.2).  For comparison, we included 7 LN samples from healthy donors and, as a 
control for a non-HIV inflammatory disease, 4 LN samples from patients undergoing 
bowel resection from IBD.  Cryopreserved LN cells were thawed and 3-5 million cells 
were stained with metal-conjugated antibodies for CyTOF.  Approximately 2 - 3 million 
thawed LN cells were separately cultured with an HIV-1 consensus B gag peptide pool or 
an overlapping set of hemagglutinin (HA) peptides from influenza virus 
(A/California/7/2009) for 3-4 weeks to expand HIV- or influenza-specific T cells, 
respectively.  In parallel, we sorted 1,464 to 15,000 naïve, memory, or GC TFH cells using 
freshly thawed LN samples for TCR sequencing analysis (Figure 5.1 and Table D.3). 
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Figure 5.1: Summary of experimental design.  Cryopreserved LN samples were obtained 
from 7 healthy controls, 4 IBD patients, and 25 HIV+ individuals. (A) Cells 
from all donors were stimulated with PMA plus ionomycin and analyzed on 
CyTOF.  (B) LN cells from 8 HIV+ donors were sorted by naïve (CD45RO-
CXCR5-CCR7+CD27+), memory (CD45RO+CXCR5-PD1-ICOS-), or GC 
TFH phenotype (CD45RO
+CXCR5+PD1+CD57+) for TCR sequencing.  (C) 
A subset of these donors also had enough cells for peptide stimulation in 
culture (5 for Gag and 6 for HA).  After 3-4 weeks, cultured cells were 
restimulated with peptides and sorted for activation by CD69 and CD40L 
expression.  TCR sequences obtained from Gag or HA-peptide reactive T 
cells were used as a reference sequence dataset to identify matching HA- or 
Gag-specific T cells from sorted and sequenced bulk populations from (B). 
Figure produced by L.F.S. 
To interrogate the functional features of GC TFH cells, LN cells were stimulated 
with phorbol-12-myristate-13-acetate (PMA) and ionomycin in the presence of Brefeldin 
A and monensin for 5 hours to capture cytokine secretion. Cells were then stained with a 
panel of metal-conjugated antibodies and acquired on the mass cytometer CyTOF 2.  
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Data from each sample were normalized using a bead-based normalizer.  We initially 
performed manual gating to identify GC TFH cells (Figure D.1).  Consistent with prior 
studies, our data demonstrated an increase in GC TFH cells during chronic HIV infection 
both by relative frequency and total cell count (Figure 5.2A,B).  To begin to interrogate 
the phenotypic diversity of GC TFH cells, data for CD4
+ T cells from all donors were 
downsampled to obtain equal numbers of cells per disease category and imported into 
Cytobank for t-SNE (t-Distributed Stochastic Neighbor Embedding) using the viSNE 
implementation.  This dimensionality reduction method creates a two-dimensional plot 
that places cells with similar phenotypic characteristics in close proximity.  As expected, 
TFH cell markers such as CXCR5, PD-1, ICOS, and BCL6 show overlapping expression 
patterns on the global t-SNE map (Figure 5.2C).  Notably, while the GC TFH cell subset 
marker CD57 co-localizes with other TFH cell markers, CD57
+ cells segregate into two 
discrete and well-separated regions (Figure 5.2D).  The first region (1) is detectable in all 
three cohorts, whereas the second region (2) shows a distinct pattern of distribution and is 
most prominently observed in LN cells from HIV+ samples (Figure 5.2D).  These data 
provide the initial evidence to suggest that there may be distinct types of GC TFH cells 




Figure 5.2: High-dimensional analysis of lymphoid CD4+ T cells identified distinct 
populations of CD4+ T cells with high CD57 expression.  (A) The frequency 
of GC TFH cells as a percentage of total CD4
+ T cells in the LN.  (B) The 
numbers of GC TFH cells detected from 3-5 million CD4
+ T cells in each HC 
or HIV+ sample (HC: n= 7, HIV n = 25).  Bar indicates the mean.  Statistical 
significance was analyzed using two-tailed Student’s t-test.  ** P < 0.005; 
*** P < 0.0005.  (C) CD4+ T cells were analyzed using the viSNE 
implementation in Cytobank and visualized on a two-dimensional t-SNE 
map.  Data combine samples from all donors and show expression intensity 
for BCL6, CXCR5, ICOS, and PD-1.  (D). t-SNE plot showing two discrete 
regions of high CD57 expression (1) and (2).  Inset showing (1) and (2) in 
equal numbers of CD4+ T cells from HC, IBD, or HIV+ samples. Data and 
figure produced by L.F.S. 
5.2.2 HIV drives expansion of an IL-21-dominant GC TFH phenotype  
To further dissect the heterogeneity within GC TFH cells, GC TFH cells were 
defined according to Figure D.1 and analyzed by t-SNE (Figure D.1 and Figure 5.3A).  
The two-dimensional t-SNE map was visualized using a contour plot to facilitate manual 
gating of discrete cell populations, an approach that has been successfully applied by 
others to demarcate phenotypically similar clusters14 (Figure 5.3B).  This method 
generated 16 phenotypic clusters. The staining intensity for each phenotypic and 
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functional marker was visualized as a heatmap for these clusters (Figure 5.3C).  For 
comparison, staining intensity is shown for memory cells (CD45RO+CXCR5-PD1-ICOS-) 
and naïve cells (CD45RO-CXCR5-CD27+CCR7+) at the bottom of the heatmap. As 
expected, many GC TFH clusters express classical TFH cell markers, including ICOS, 
BCL6, and IL-21.  However, we also detected a Foxp3 and CD25-expressing cluster that 
resembles T follicular regulatory cells (TFR) (cluster 13) and a few unexpected clusters 






Figure 5.3: Cellular heterogeneity of GC TFH cells across HC, IBD, and HIV patient-
derived LNs.  (A) Representative gates used to identify GC TFH cells for t-
SNE analysis. (B) All GC TFH cells from 36 samples were concatenated and 
displayed on a two-dimensional t-SNE map.  Manual gating was performed 
to identify t-SNE clusters based on contour map (left).  Each cluster was 
assigned an arbitrary number and overlaid onto the t-SNE map (right).  (C) 
Heatmap shows raw staining intensity of each marker within each cluster 
defined in (B) after arcsinh transformation. Staining intensities for each 
marker are shown for memory and naïve cells at the bottom of the heatmap 
for comparison.  (D) Heatmap showing the frequency of each cluster in GC 
TFH cells pooled by disease categories.  Cluster groups, g1-g4, are defined 
by the dendogram (right), which was generated by hierarchical clustering 
based on cluster frequency in each sample type.  (E) Stacked bar chart 
showing normalized frequency of phenotypic group distribution for each 
sample.  HIV+ samples were ordered by increasing CD4+ T cell count (7 – 
1136). Data and figure produced by L.F.S. 
To determine which GC TFH cell features represent the baseline state and which 
are enriched in disease, we pooled GC TFH cells by disease category and measured the 
percentage of each cluster in HC, IBD, or HIV-patient derived samples.  Hierarchical 
clustering was then applied on cell frequencies with respect to disease state to identify 
clusters that are shared by individuals in the same clinical category (Figure 5.3D).  This 
analysis partitioned the 16 clusters into four major phenotypic groups (g1-g4, Figure 
5.3D).  In general, clusters assigned to groups g1 and g2 were enriched for classical TFH 
cell markers, such as ICOS and BCL6, and expressed higher levels of IL-21.  In contrast, 
fewer clusters belonging to groups g3 and g4 expressed ICOS, BCL6, or IL-21.  Group 
g3 was comprised mostly of cytokine-low GC TFH cells, including the TFR subset.  Group 
g4 contained cells that predominantly produce non-TFH defining effector molecules, such 
as TNF-α, IFN-γ, and granzyme A. The distribution of these phenotypic groups was 
distinct when comparing HC, IBD, and HIV samples.  For example, HIV LNs contained 
the highest frequencies of g1 and lowest frequencies of g3 and g4. IBD LNs were 
enriched for g3, whereas HC LNs contained the highest frequencies of g4 (Figure 5.3D, 
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Figure D.2).  Phenotypic group analysis on individual sample-level data showed a 
similar pattern with some differences between individuals (Figure 5.3E).  Notably, our 
cohort contains three HIV+ outliers that appeared more HC-like (H18, H23, and H24, 
Figure 5.3E).  These samples came from patients who maintained a better CD4+ T cell 
count without treatment and included an HIV controller with undetectable viral load 
(H18).  Collectively, these data illustrate the heterogeneity of GC TFH cells. While IBD 
and HIV are both diseases with sustained chronic inflammation, our high dimensional 
data revealed unique features of GC TFH cells in each disease and highlight the 
accumulation of a dominant GC TFH population with defined activated features in most 
HIV+ patients during chronic HIV infection that are distinct from IBD.  
As a result of expanding selected cellular subsets, GC TFH cells in HIV
+ samples 
may become less functionally diverse. To test this, we examined the breadth of cytokines 
produced by GC TFH cells. In particular, we focused on the characteristics of IL-21-
producing cells to distill the complexity of the dataset, as IL-21 is a key cytokine that 
mediates TFH cell function.  We performed manual gating to identify GC TFH cells that 
express IL-21 upon stimulation.  We then compared IL-21+ TFH cell frequency in HIV
+ 
samples to the expected baseline levels from HCs. Consistent with the preferential 
contribution of HIV+ samples to the phenotypic group g1, IL-21-expressing GC TFH cells 
were increased in infected LNs compared to cells from HCs both by percentage and 
absolute cell number (Figure 5.4A,B). To assess poly-functionality, we measured the co-
expression of IL-21 with other effector molecules in our antibody panel, which includes 
IFN-γ, TNF-α, IL-2, IL-4, and granzyme A.  Different combinations of cytokine 
producing subsets were generated by Boolean gating on IL-21+ GC TFH cells.  Cytokine-
positive gates were then grouped according to the number of cytokines.  This divided GC 
TFH cells into categories based on the number of effector molecules that were co-
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expressed with IL-21, revealing a different distribution of cells in HIV+ and HC samples.  
For example, over 40% of IL-21-producing GC TFH cells in HCs simultaneously 
produced 2 other cytokines (IL-21+2), whereas on average only 18% of cells in the HIV+ 
samples were in the same category.  Instead, samples from HIV+ patients were skewed 
toward single IL-21-producing cells (IL-21 only) (Figure 5.4C).  To determine if this 
finding is a general characteristic that extends beyond GC TFH cells, we also examined 
IL-21-related functional responses in other TFH cell populations.  To ensure that we 
captured additional TFH cells in different stages of differentiation, we broadly defined TFH 
cells by CXCR5 expression on memory CD4+ T cells.  Analysis of IL-21-producing 
CXCR5+ cells revealed a similar pattern with a statistically significant decrease in IL-
21+2 cell subsets and a corresponding increase in IL-21 only cells in HIV+ samples 
compared to HCs (Figure 5.4D).   Notably, poly-functionality of IL-21 producing TFH 
cells was associated with distinct B cell phenotypes.  Past studies have demonstrated 
fewer memory B cells and higher frequencies of plasma cells in viremic HIV+ LNs15, 16.  
Here, we identified B cell populations using the same gating strategy as Perreau et al. and 
found that a low frequency of isotype-switched memory B cells was associated with more 
single IL-21-producing cells (IL-21 only) and fewer poly-functional (IL-21+2) TFH cells 
(Figure D.3, Figure 5.4E,F). A reciprocal relationship was observed for plasma cell 
frequency, for which a higher frequency was associated with more IL-21 single producers 
and fewer IL-21+2 TFH cells (Figure D.4).  Further analysis on individual cytokine-
positive populations pointed to a decrease in triple IL-21, IL-2, and TNF-α-producing 
TFH cells as one of the main differences between HIV
+ and HC LNs (Figure D.5).  We 
also compared IL-21-secreting GC TFH cells between HIV and IBD samples to further 
define similarities and differences under different types of chronic inflammation.  This 
showed a substantial fraction of IL-21-single-positive population within IL-21-producing 
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TFH cells in IBD samples, suggesting that the emergence of a dominant IL-21-producing 
phenotype may be a shared characteristic of chronic inflammation (Figure D.6). 
However, there were differences between HIV+ and IBD LNs in other cytokine 
combinations, including an IL-2 and IL-21-double-positive phenotype that was more 
frequently expressed in IBD LNs, again highlighting disease-specific features between 





Figure 5.4: IL-21-secreting TFH cells in HIV
+ patients acquire an activated phenotype and 
restricted functional diversity. (A,B) The number and frequency of IL21+ 
TFH cells as a percentage of cytokine producing GC TFH cells.  The 
denominator includes GC TFH cells that produce any combination of IL-2, 
IFN-γ, TNF-α, IL-4, IL-21, and granzyme A. (C,D) Pie charts and bar 
graphs summarizing the frequency of IL-21+ TFH cells that produce only IL-
21 or IL-21 plus 1, 2, 3, or 4 other effector molecules (IL-2, IFN- γ, TNF- α, 
IL-4, or granzyme A) in the GC subset (C) or CXCR5+CD45RO+CD4+ T 
cells (D) from HC or HIV+ LNs.  (E,F) Correlation between switched 
memory B cell frequency and the frequency of IL-21 only or IL21+2 
producing CXCR5+CD45RO+ cells.  Data include all LNs (See also Figure 
D.4).  (G,H) The frequency of CD38+ or Ki67+ GC TFH cells.  (I) 
Correlation between the frequency of CD57+PD1+ cells and Ki67+ GC TFH 
frequency. Data include all LNs. Statistical analysis using Student’s t-test 
was corrected for multiple comparisons using Holm-Sidak method, with 
alpha=5%.  Error bars represent SEM.  Association is measured by 
Spearman rank correlation and least squares fit regression. * P < 0.05, ** P 
< 0.005; *** P < 0.0005. Data and figure produced by L.F.S. 
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5.2.3 GC TFH cells in HIV+ patients have undergone clonal expansion   
We next sought to understand the mechanisms that drive the expansion of GC TFH 
cells during HIV infection.  In addition to higher IL-21 level, we also detected higher 
CD38 and Ki67 expression in GC TFH cells from HIV
+ patients, suggesting that the 
changes to TFH cells during HIV infection may be induced by T cell activation (Figure 
5.4G,H).  In addition, the frequency of Ki67+ cells correlated with the expression of GC 
features in the CXCR5+ subset, suggesting that cellular proliferation may contribute to an 
accumulation of GC TFH cells during chronic HIV infection (Figure 5.4I).   
How HIV drives GC TFH cell proliferation and expansion remains unclear.  The 
expansion of GC TFH cells may result from an overall non-specific inflammatory state 
that stimulates a large, diverse group of TFH cells to proliferate.  Alternatively, GC TFH 
proliferation could reflect expansion of a smaller set of HIV-specific T cell clones. To 
test these different possibilities, we performed TCR sequencing on sorted naïve, CXCR5- 
memory, and GC TFH cells directly from LN cell suspension without stimulation.  TCRs 
were sequenced using molecular identifiers (MID) to tag TCR transcripts similar to 
previously published studies17, 18 (Chapter 2). This effectively increases the accuracy 
130 times compared to the first generation of immune repertoire sequencing19, 20, 21 and 
also enables accurate quantification of TCR transcript abundance.  The number of 
transcripts detected for a particular CDR3 sequence was then used to define TCR clone 
size.  On average 11,839 TCR transcripts were detected for each sample (Table D.3). 
Unique TCR frequencies range from 1 in 37,129 (0.003%) for the rarest clones to 250 in 
2,498 (~10%) for the most expanded clone. To compare the degree of relative clonal 
expansion, we categorized TCR frequency into 6 groups (rare to >2%) according to the 
clone size relative to the total TCR transcripts detected in that sample (Figure 5.5A). As 
expected, the TCR repertoire of naïve CD4+ T cells was composed mostly of rare clones 
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(<0.1%).  In contrast, the TCR repertoire of GC TFH cells had a much higher fraction of 
TCRs occupied by abundant clones (>0.1%) compared to naïve and memory CD4+ T 
cells (Figure 5.5A). The overall diversity of the TCR repertoire was measured by 
normalized Shannon entropy (NSE), which quantifies the degree of clonal expansion22, 23. 
NSE varies between 0 and 1: 0 if all sequences are the same and 1 if all the sequences are 
unique. Consistent with the hypothesis that the increase in GC TFH cell frequency is due 
to selective proliferation of certain T cell clones, NSE analysis revealed that GC TFH cells 
exhibit significantly more clonal expansion than naive and memory cells (Figure 5.5B). 




Figure 5.5: GC TFH cells are clonally expanded. (A) Breakdown of the proportion of the 
TCR repertoire represented by clones of different sizes for sorted naïve, 
memory, and GC TFH cells from HIV
+ LNs. TCR clone size was normalized 
by the total number of TCR transcripts on nucleotide (nt) sequences, with 
darker green for TCR clones covering a larger percentage of total number of 
transcripts and lighter green for TCR clones covering a smaller percentage 
of total number of transcripts), (B) Normalized Shannon entropy of the TCR 
repertoire of sorted naïve (black), memory (blue), and GC TFH (orange) 
cells. Grey lines connect samples from the same patient. Sample ID is 
shown above each bar graph.  Bars indicate means. * P < 0.05 by two-tailed 
Wilcoxon signed-rank test. 
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5.2.4 GC TFH cells show signatures of antigen-driven clonal convergence 
The evidence of clonal expansion in GC TFH cells prompted us to ask whether or 
not the clonal expansion was antigen-driven. To address this question, we analyzed the 
TCR sequences for evidence of convergence to the same amino acid sequence from 
distinct nucleotide sequences.  Unlike B cells, which can undergo somatic hypermutation, 
the TCR sequence of a naïve T cell is determined during maturation in the thymus and 
remains fixed throughout the lifespans of the T cell and its progeny. Thus, with the 
exception of clones that express 2 TCR α or β sequences, distinct TCR nucleotide 
sequences necessary arise from distinct naïve T cells. However, multiple nucleotide 
sequences of different TCRs may encode the same amino acid sequence.  These 
degenerate TCR sequences are typically rare, and the presence of these sequences suggest 
antigen selection pressure that favors certain TCR motifs that recognize particular 
antigen(s) (Figure 5.6B).  Thus, having highly abundant CDR3 amino acid sequences 
that are encoded by multiple distinct nucleotide sequences indicates preferential 
expansion of T cells with that specificity22.  On the other hand, we would not expect 
multiple nucleotide sequences to converge on the amino acid level in the absence of 
strong antigen-driven selection. Following this logic, we translated the TCR nucleotide 
sequences into amino acid sequences and tallied the number of different nucleotide 
sequences that encode each CDR3 amino acid sequence. These CDR3 amino acid 
sequences can be broken into 4 quadrants based on the level of degeneracy and frequency 
in the repertoire (Figure 5.6A and Figure D.7). Q1 contains highly expanded amino acid 
CDR3 sequences that are encoded by 2 or more nucleotide sequences. These degenerate, 
abundant clones likely arose from strong antigen-driven selection and proliferation. Q2 
contains low frequency amino acid CDR3 sequences that are also encoded by 2 or more 
nucleotide sequences. Degenerate clones may originate from naïve T cells, but these are 
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typically rare as reflected by the low frequency of non-clonally expanded sequences in 
Q2.  Q3 contains amino acid CDR3 sequences that show neither clonal expansion nor 
amino acid convergence and make up the majority of the repertoire. Q4 contains 
expanded amino acid CDR3 sequences derived from a single nucleotide sequence and are 
therefore non-degenerate. This TCR degeneracy analysis revealed a significant degree of 
antigen-driven clonal convergence in GC TFH cells compared to naïve and memory T 
cells (Figure 5.6C). Together with the NSE decrease in GC TFH, these data provide 
further evidence that the observed increase in GC TFH frequency was due to antigen-




Figure 5.6: Antigen-driven clonal selection signature in GC TFH cells of HIV
+ LNs. (A) 
Representative degeneracy plot from sample H2.  Coding degeneracy level 
(number of unique TCR nucleotide (nt) sequences encoding a common 
CDR3 amino acid (aa) sequence) of each CDR3 aa sequence is plotted 
against their frequency (measured as % of total TCR transcript) in naïve, 
memory, and GC TFH cells. Each dot is a unique CDR3 aa sequence. Red 
dashed lines indicate cutoffs for degenerate (2 or more nt sequences coding 
for the same aa sequence, horizontal) and expanded (0.1% or more of TCR 
transcripts, vertical) clones. Each panel is broken into 4 quadrants: Q1: 
degenerate-abundant clones; Q2: degenerate-rare clones; Q3: 
nondegenerate-rare clones; Q4: nondegenerate-abundant clones. Red arrow 
points to example degenerate clone in (B). (B) An example of CDR3 aa 
degeneracy. aa (top row) and nt (bottom row) sequences for each of 3 
distinct nt sequences (0.41% of total TCR transcripts) that code for the same 
aa sequence as the arrow points in (A) with Y=3, X=0.41%. Red boxes and 
highlights indicate redundant codons. (C) Comparison of Q1 degenerate-
abundant clone percentage in naïve (black), memory (blue), and GC TFH -
(orange) cells. Grey lines connect samples from the same patient. Bars 
indicate means. *P < 0.05 by two-tailed Wilcoxon signed-rank test. 
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5.2.5 GC TFH cells contain HIV-specific T cells  
We hypothesized that the antigen-driven clonal expansion observed in GC TFH 
cells of HIV+ LNs was caused by HIV viral antigens. To this end, we examined the 
antigen-specificity of GC TFH cells by establishing donor-specific reference panels of 
HIV-reactive TCR sequences (Figure 5.7).  This was performed by culturing LN cells 
from five HIV+ patients with an overlapping pool of HIV-1 Gag peptides for 3-4 weeks, 
then identifying specific antigen-reactive T cells by CD40L and CD69 expression upon 
peptide restimulation.  As a control for non-HIV related clonal expansion, we also 
cultured and stimulated cells from the same subjects plus one more with overlapping 
peptides from hemagglutinin (HA) of influenza virus. TCR sequences obtained from 
these cells were used to identify Gag-specific (Figure 5.7) or HA-specific (Figure D.8) 
TCRs from bulk T cell sequences, which were obtained from freshly thawed LN cells 
that had not been stimulated.  By comparing the CDR3 nucleotide sequences from Gag-
specific LN cells to bulk naïve, memory, and GC TFH cells, we could trace the overlap in 
TCR sequences between Gag-specific LN cells and other cell populations. This analysis 
was illustrated in circos plots (Figure 5.7A): the perimeter was divided into four sections 
corresponding to the four cell populations (Figure 5.7A, outer circle). Each thin slice of 
the arc represents a unique TCR sequence, ordered by the size of that sequence, from the 
most abundant clones (dark green, 5 or more TCR transcripts) to the rarest clones (light 
green, single TCR transcript) (Figure 5.7A, inner circle). Identical TCR sequences that 
are shared between the Gag-specific population and naïve, memory, or GC TFH cells were 




Figure 5.7: GC TFH cells exhibit HIV-antigen-driven clonal expansion and selection. (A) 
Gag-specific TCR clones overlap with HIV+ LN CD4+ T cell populations. 
Each thin slice of the arc represents a unique TCR sequence, ordered by the 
clone size (darker green for larger clones, inner circle). Grey curves indicate 
Gag-specific TCR clones (nt sequences) found in naïve (black, outer circle), 
memory (blue, outer circle), and GC TFH (orange, outer circle) populations. 
(B) Number of Gag-specific TCR clones observed in naïve (black), memory 
(blue), and GC TFH (orange) populations. Grey lines connect samples from 
the same patient. Bars indicate means. (C) Mean clone size of Gag-specific 
clones (magenta) and clones of unknown specificity (black) from naïve, 
memory, and GC TFH populations. (D) Degeneracy, or the number of 
distinct nt sequences per CDR3 aa sequence, of Gag-specific clones 
(magenta) and clones of unknown specificity (black) from naïve, memory, 
and GC TFH populations. Data from all 5 subjects were aggregated for C and 
D. Error bars indicate SEM. ** P < 0.01, *** P < 0.001 by two-tailed 
Student’s t-test. 
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We found several Gag-specific TCR sequences in the memory (0 to 4 clones) and 
GC TFH (2 to 9 clones) populations, while the overlapping was minimum in naïve T cells 
(0 or 1 clones) (Figure 5.7B).  Analysis of combined TCR sequencing data from all 
individuals clearly showed that these Gag-specific GC TFH cells, and to a lesser extent the 
Gag-specific memory cells, were highly expanded compared to the rest of the T cells 
with the same phenotypes but unknown specificity (Figure 5.7C).  As expected, naïve T 
cells minimally overlap with Gag-specific TCR sequences, and the few sequences that 
overlapped were not preferentially expanded (Figure 5.7C).  We also observed sequence 
overlap between GC TFH cells and HA-reactive T cells (Figure D.8).  Since influenza 
exposure contributes to HA-specific memory within circulating TFH cells and most people 
should have experienced influenza antigen either from natural infection or vaccination24, 
it was not surprising that HA-specific T cells overlapped with memory and GC TFH 
populations.  However, in contrast to the observed clonal expansion of Gag-specific T 
cells within both memory and GC TFH cell compartments, the average clone size for HA-
specific T cells is not statistically different from the background level (Figure D.8C).  
Translating these Gag-specific sequences into amino acid sequences and analyzing the 
occurrence of multiple, distinct nucleotide sequences mapping to the same amino acid 
sequence showed that the Gag-specific TCR sequences within the GC TFH population, but 
not naïve nor memory, have a significantly higher degree of coding degeneracy, 
congruent with our hypothesis that the GC TFH expansion in HIV
+ LNs is antigen-driven 
(Figure 5.7D). These data support a selective expansion of Gag-specific T cells in HIV+ 
samples, and collectively provide strong evidence for HIV-antigen-driven changes in GC 
TFH cells during chronic HIV infection.  
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5.3 DISCUSSION 
Secondary lymphoid organs are the primary sites for immune response against 
HIV, but they are also preferentially targeted by HIV for viral replication and 
persistence25.  Typically, LNs are challenging to access in humans and thus studies using 
blood and lymphoid tissues from non-human primates have laid the foundation for 
understanding the immunologic changes during chronic HIV/SIV infection. The data 
described here represent a comprehensive phenotypic and TCR analysis of GC TFH cells 
in the LNs from HIV+ patients and compares the phenotypic changes during HIV 
infection to other diseased or healthy states using IBD and HC samples.  The data show 
that GC TFH cells are functionally diverse in the LNs of healthy individuals and identify a 
disruption to the baseline heterogeneity within TFH cells during chronic inflammation.  
We used TCR repertoire sequencing analysis to further demonstrate virus-driven 
expansion of HIV-specific GC TFH cells as a key mechanism that contributes to TFH cell 
pathology in HIV-infected LNs.  
One important open question is why an excess of TFH cells in the LNs fails to 
correct for and may even contribute to impaired humoral immunity during chronic HIV 
infection. Previous studies have demonstrated functional inhibition of TFH cells by PD-L1 
expression on B cells12.  It has also become clear that there is substantial heterogeneity 
within TFH cells.  For example, Wong et al. used CyTOF to identify many subsets of 
tonsilar TFH cells from children undergoing tonsillectomy
26.  The biological relevance for 
TFH cell diversity is just now beginning to be understood.  Using IL-21 and IL-4 reporter 
genes in mice to trace distinct functional subsets TFH cells, Weinstein et al. demonstrated 
temporal differences in the kinetics of IL-21 and IL-4 production and showed that IL-21+, 
IL-21+IL-4+, and IL-4+ TFH cells each provide specialized follicular helper function and 
support distinct aspects of B cell function and development27.  Given these new insights 
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into the importance of TFH cell subsets, we sought to investigate how cellular 
heterogeneity of GC TFH cells respond to HIV infection.  Past analyses on HIV
+ LNs have 
generally used a small set of TFH cell markers that appear to be ubiquitously expressed 
across GC TFH cells, due to the technical limitation of fluorescence-based flow 
cytometry12.  Here, we applied mass cytometry to expand the analysis on GC TFH cells 
using metal isotope-conjugated antibodies against an extended list of surface and 
intracellular proteins.  Our data on LN cells from healthy individuals, IBD patients, and 
HIV+ patients revealed a high level of cellular heterogeneity in the GC TFH cell 
compartment that includes cells with the typical TFH phenotype as well as others that 
produce non-TFH restricted effector molecules in different combinations.  
During chronic HIV infection, GC TFH cells lost functional diversity and acquire a 
dominant IL-21-producing and activated phenotype.  These changes in the functional 
potential of TFH cells were associated with HIV-related changes in B cell subsets, 
suggesting that a full complement of TFH cell subsets may be necessary for normal B cell 
differentiation.  Some TFH cell features in infected LNs were shared with LNs from IBD 
patients who also experience chronic inflammation and impaired humoral response to 
vaccination28. Additionally, there were unique HIV-related changes such as low 
frequencies of phenotypic groups g3 and g4 that expressed low levels of IL-21.  
Differences in susceptibility to viral infection and/or virus-induced cytopathology in 
infected LNs may change the distribution of TFH cell populations.  TFH subsets could also 
compete with and/or regulate each other, either directly or indirectly, by impacting other 
cell types.  Along this line, a major population decreased in HIV+ LNs produces IL-2, 
which is a cytokine that antagonizes TFH cell differentiation through Stat5-dependent 
activation of Blimp-129, 30.  Whether IL-2-dependent pathways have a role in maintaining 
TFH cell diversity is a key question for future studies.  Taken together, high-dimensional 
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CyTOF analysis revealed the diversity of GC TFH cells in LNs.  Our data also support the 
general notion that the cellular environment in HIV+ LNs is highly pro-inflammatory and 
additionally highlight the changes in GC TFH cells that are unique to HIV infection.  
How HIV promotes changes in GC TFH cell compartment is incompletely 
understood. The observation of high levels of CD38 and Ki67 expression suggested that 
GC TFH cells accumulate from T cell activation. However, whether the expansion of GC 
TFH cells is a result of an overall hyperactive inflammatory state and/or a specific HIV 
antigen-driven response is not known. Past studies in mice have demonstrated a critical 
role for sustained antigen availability in the maintenance and differentiation of GC TFH 
cells31.  While in these studies TCR engagement is assumed, a direct role for TCRs in GC 
TFH cell proliferation has not yet been demonstrated.  To answer this question, we 
performed TCR sequencing to precisely define the repertoire composition of GC TFH 
cells in HIV+ LNs. Our data revealed that a small portion of these clones harbor distinct 
nucleotide sequences that converge to the same amino acid sequence – a signature of 
antigen-driven selection. In addition, convergent TCRs are significantly more common in 
GC TFH cells compared to memory or naïve cells. These data strongly suggest that HIV-
derived antigens directly activate T cells to promote TFH cell pathology in the GC 
compartment.  To test this, we identified HIV-specific TCR sequences from Gag-
stimulated T cells from the same LNs. Mapping these HIV-specific TCR sequences back 
onto the GC TFH TCR repertoire revealed that the Gag-specific T cells in the GC 
compartment were greatly expanded. The larger clone size and the prevalence of 
degenerate nucleotide sequences mapping to the same amino acid sequences in HIV-
reactive T cells compared to HIV-nonreactive T cells provided further evidence for an 
HIV-antigen-driven process that leads to the expansion of GC TFH cells during chronic 
HIV infection. 
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In conclusion, we identified the expansion of a dominant GC TFH cell population 
that expresses a defined activated phenotype that is driven by viral antigens during 
chronic HIV infection.  Our combination of high dimensional protein expression and 
TCR repertoire sequencing analyses provided a powerful platform to interrogate GC TFH 
cell biology and revealed a previously unappreciated level of heterogeneity and poly-
functionality within GC TFH cells at a healthy baseline. Despite their crucial role in GC 
formation and B cell help, the significantly higher frequencies of GC TFH cells in HIV
+ 
LNs fail to induce a robust antibody response against the infection. Our data suggest that 
HIV-driven activation of GC TFH cells in an antigen-specific manner diminishes their 
poly-functionality, and the emergence of an activated IL-21-constricted phenotype likely 
contributes to TFH cell dysfunction in severe HIV infection and other conditions of 
chronic inflammation.  Our results highlight the complexity of TFH cells in the LNs and 
suggest that therapies aiming to restore TFH cell diversity may improve B cell responses 
in HIV infection.   
5.4 METHODS 
5.4.1 Human lymph node collection and isolation 
The HIV+ cohort was composed of 25 Mexican individuals. LN excision was 
obtained from palpable cervical LNs for clinical diagnostic workup and after written 
informed consent was obtained. Recruitment of study subjects was approved by the 
Comité de Ciencia y de Ética en Investigación and the Comité de Investigación of the 
Instituto Nacional de Enfermedades Respiratorias (INER) in México City. LN biopsies 
from HIV+ patients were placed in Hanks medium (Lonza) and immediately processed by 
cutting the tissue in small pieces with a scalpel and cells were dissociated using Gentle 
MACS tissue dissociator (Miltenyi Biotec). Single cell suspensions were washed and 
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cryopreserved.  All IBD LNs and 2 HC LNs were obtained through Cooperative Human 
Tissue Network (CHTN) from individuals undergoing clinically indicated bowel 
resection for IBD or for benign polypectomy.  LNs were dissected from peri-colonic 
adipose tissues shipped overnight in RPMI media.  The remaining 4 HC LNs were from 
iliac region of transplant donors and 1 cervical LN sample was obtained by combining 
cells from 5 autopsy donors after Ficoll density centrifugation, which was necessary due 
to poor viability.  All samples were de-identified and obtained with IRB regulatory 
approval from University of Pennsylvania.  Subject characteristics are shown in Table 
D.2.   
5.4.2 Stimulation and antibody staining for CyTOF 
Cryopreserved cells were thawed in 0.025 unit/mL of benzonase (Sigma), 
washed, and stimulated with 5ng/ml of PMA (Sigma) and 50ng/ml ionomycin (Sigma) in 
the presence of 2mM Monensin (Sigma) and 5ug/ml Brefeldin A (Sigma) at 37⁰C for 5 
hours.  After stimulation, cells were washed and incubated in 1uM cisplatin (Fluidigm) 
for 5 min, followed by staining with surface antibody cocktail for 30 min at room 
temperature (Table D.1). Metal conjugation of CyTOF antibodies was performed 
according to the manufacturer protocol using the X8 Maxpar kit (Fluidigm).  For 
intracellular staining, cells were permeabilized and fixed using Foxp3 staining buffer set 
(eBioscience) and incubated with the intracellular antibody cocktail for 1 hr at room 
temperature (Table D.1). After staining, cells were washed three times then resuspended 
in 2% paraformaldehyde (Electron Microscopy Sciences) with 125nM iridium 
intercalator (Fluidigm) for an overnight incubation at 4⁰C.  The next day, cells were 
washed three times, including a final wash in distilled water, and resuspended in PBS 
containing normalization beads before acquisition on CyTOF 2. 
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5.4.3 Data analysis for CyTOF 
CyTOF FCS files were normalized using bead standards with the Matlab-based 
Nolan lab normalizer.  Iridium+CD3+CD19-TCRαβ+CD4+ T cells were excluded for 
doublets and beads and downsampled to a maximum of 13,910 cells per donor sample 
using Flowjo’s downsampling plug-in to ensure that each sample type contributes equal 
numbers of CD4+ T cells to the data analysis.  FCS files were imported into Cytobank for 
t-SNE analysis using viSNE implementation. For Figure 5.2, cluster markers include the 
following: CD57, CD5, IFN-γ, CCR6, CD69, granzyme A, TNF-α, CD45RO, CD27, 
Ki67, BCL6, IL-4, CD25, Eomes, ICOS, Foxp3, CD96, CD45RA, CCR7, CXCR5, T-bet, 
PD-1, IL-21, IL-2, CXCR3, and CD38.  ViSNE were set with iteration = 5000, perplexity 
= 45, theta = 0.5. For the analysis on GC TFH cells, GC TFH cells were defined according 
to Figure D.1. All GC TFH cells were exported from Flowjo and imported into Cytobank 
using the following implementation (cluster markers: CD57, IFN-γ, CCR6, CD69, 
GranzymeA, TNF-α, CD27, Ki67, BCL6, CD25, Eomes, ICOS, Foxp3, CD95, CXCR5, 
PD-1, IL-21, IL-2, CXCR3, CD38, iteration = 2000, perplexity = 30, theta = 0.5). 
Heatmaps were generated using the "gplot" package in R and show the raw staining 
intensity of each marker after arcsinh transformation. Heatmap dendograms were 
clustered by Euclidean distance. CCR5 (156) and BLyS (158) were not included due to 
significant spill over from isotope impurity by Ki67 (157). 
5.4.4 TCRβ library generation and sequencing 
Cryopreserved cells were thawed in 0.025 unit/mL of benzonase (Sigma), 
washed, and stained with CD4-AF700 (OKT4, eBioscience), CD11b-PE/cy5 (ICRF44, 
Biolegend), CD19-PE/cy5 (HIB19, Biolegend), and CD8-PE/cy5 (HIT8a, Biolegend) in 
the dump channel, fixable aqua dye (ThermoFisher) for live/dead discrimination, CD57-
FITC (HCD57, Biolegend), CD45RO-BV605 (UCHL1, Biolegend), CXC5-PE/TexasRed 
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(J252D4, Biolegend), ICOS-APC (C398.4, Biolegend), PD-1-BV785 (EH12.2H7, 
Biolegend), CCR7-PE/cy7 (G043H7, Biolegend).  For direct sequencing, thawed cells 
were sorted by naïve (CD45RO-CXCR5-CD27+CCR7+), memory (CD45RO+CXCR5-
PD1-ICOS-), or GC TFH cell phenotypes (CD45RO
+CXCR5+PD1+CD57+).  To identify 
antigen-specific T cells, 2-3 million cells were stimulated with 0.5 ug/ml of pooled HA 
hemagglutinin (HA) peptides from influenza virus (A/California/7/2009) or HIV-1 
consensus B gag peptide (Gag 8117, NIH AIDS Reagent Program) in 48-well plates.  
Cells were cultured for 3-4 weeks, then restimulated with 5 ug/ml of the same peptide 
pool in the presence of 2 ug/ml of anti-CD40 (HB14, Biolegend).  Activated T cells were 
sorted by positive staining for CD40L (24-31, Biolegend) and CD69 (FN50, BD 
biosciences). TCR library generation and sequencing on FACS-sorted naïve, memory, 
GC TFH, and Gag- or HA-reactive T cells was performed using molecular barcodes 
similar to what has been described previously 17, 18. Briefly, FACS-sorted cells were 
lysed, and total RNA was purified using AllPrep DNA/RNA Micro Kit (Qiagen catalog # 
80284). 30% of the purified RNA was used for library generation. Most of the libraries 
were sequenced on Miseq 2x250 PE mode with some sequenced on Hi-seq 2x150 PE 
mode depending on run availability at the sequencing core. Primers are listed in Table 
D.4. 
5.4.5 Sequencing data processing and analysis 
Raw reads processing was performed similar to the method previously described 
in Chapter 2 Methods 2.4.2-4. Briefly, consensus sequences were constructed within 
each MID group. Consensus TCR sequences were subjected to the CDR3 blast module of 
MIGEC 18 to assign V and J alleles and parse out the CDR3 sequence. Each set of V 
allele, J allele, and CDR3 sequence is equivalent to a TCR transcript. TCR transcripts 
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with the same V allele, J allele, and CDR3 sequence were merged to unique TCR 
sequences, or TCR clones. 
5.4.6 Clone size distribution and normalized Shannon entropy 
The size of each TCR clone was determined by the number of TCR transcripts of 
that sequence detected. The sizes were then normalized by the total number of TCR 
transcripts detected in that sample to yield the relative clone size in percent. These sizes 
were binned into 6 groups, and the total percent of TCR transcripts represented by each 
group was displayed in Figure 5.5A. Normalized Shannon entropy was calculated as 
previously described22, 23. 
5.4.7 Amino acid translation and degeneracy 
The CDR3 blast module of MIGEC18 was used to translate the CDR3 nucleotide 
sequences into amino acid sequences. For each amino acid CDR3 sequence, the number 
of distinct nucleotide sequences (TCR clones) encoding that amino acid CDR3 sequence 
was tallied as the degree of degeneracy22. Amino acid CDR3 sequences encoded by 2 or 
more TCR clones were labeled as degenerate, and degeneracy versus relative clone size 
was analyzed to identify expanded, degenerate clones. 
5.4.8 Antigen-specific TCR identification 
TCR clones from the peptide-stimulated cells were used to establish donor-
specific Gag- and HA-specific TCR sequences. TCR clones found in both the Gag- and 
HA-stimulated cultures were eliminated, as they likely originated from basally activated 
T cells within the initial LN sample. These antigen-specific sequences were then queried 
in the bulk naïve, memory, and GC TFH cells to identify Gag- and HA-specific clones 
within the respective populations. Circlize R package32 was used to visualize circos plots 
in Figure 5.7A and Figure D.8A. The Gag- and HA-specific clones were isolated from 
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the rest of the TCR clones, and the clone size and degeneracy were then compared 
between the antigen-specific TCR clones and the bulk clones (Figure 5.7C,D and Figure 
D.8C,D). 
5.4.9 Statistics 
For pair-wised analysis comparing a single variable in the CyTOF-based 
phenotypic analysis, statistical significance was analyzed using Student’s t-test.  
Spearman rank correlation and least squares fit regression were applied to measure the 
degree of association. For TCR repertoire analysis, Wilcoxon signed-rank test was used 
to compare paired samples, i.e. naïve, memory, and GC TFH cells from matched subjects. 
A P-value of < 0.05 was used as a cutoff for statistical significance. For three-way 
comparison, significant P-value is decreased to < 0.0167. Statistical analyses were 
performed using GraphPad Prism. 
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Chapter 6: Conclusions and Future Studies 
We developed an improved IR-Seq method, MIDCIRS, and applied it to study the 
antibody repertoire response to malaria in young children and the perturbation of the TFH 
compartment during HIV infection. MIDCIRS utilizes a 12N barcode to track individual 
mRNA transcripts through PCR amplification and sequencing. Due to the stochastic 
nature of the randomized barcodes, especially for samples containing a large number of 
transcripts, distinct mRNA transcripts may happen to be labeled with identical barcodes. 
We performed a sequence-similarity-based clustering step to recognize these occurrences 
and further separate MID groups into sub-groups, with each sub-group representing an 
mRNA molecule. Using naive B cells at varying cell counts, we developed a set of 
metrics than can be used to validate future IR-Seq methods and experiments. We showed 
that MIDCIRS has excellent diversity coverage down to as few as 1,000 cells, setting it 
apart from other IR-Seq methods. MIDCIRS is extremely useful for analyzing precious 
samples involving low blood draw volumes and/or rare cell types. 
This aspect of MIDCIRS made it perfect to interrogate the infant and toddler 
antibody repertoire. The predictable annual malaria season in Western Africa opened up 
the possibility of studying the age-related development of the antibody repertoire and its 
capacity to respond to a natural infection. We found that the infant antibody repertoire is 
surprisingly competent. While the overall SHM load is low in infants, they have the 
ability to produce a small fraction of highly mutated antibodies. Upon acute malaria 
infection, infants significantly diversify their B cell clonal lineages, on par with what we 
observed in toddlers. The high coverage of MIDCIRS allowed for us to discover antibody 
sequences during acute malaria that could be traced back to memory B cells from the pre-
malaria timepoint in toddlers who had previously experienced malaria. The acute progeny 
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of these memory B cells harbored significantly more mutations, and we found isotype 
switched sequences stemming from IgM-expressing memory B cells, highlighting the 
ability of memory B cells to further induce SHM and class switch during a secondary 
infection.  
Despite the apparent competence of the infant antibody repertoire, children in 
malaria-endemic regions fail to develop sterile immunity to malaria and only develop 
clinical immunity around the age of 7 years old. It will be of great interest to extend this 
antibody repertoire analysis to older children to pinpoint differences that lead to clinical 
immunity. A longitudinal cohort combined with the multiple timepoint lineage approach 
we showcased could trace the evolution of B cell clonal lineages that contribute to this 
immunity, possibly shedding light on why repeated infections are necessary to establish 
clinical immunity to malaria. Understanding the mechanism of natural immunity to 
malaria could be a key step towards improving malaria vaccine strategies, as the current 
best vaccine only offers limited protection, especially for infants. 
MIDCIRS reduces the error rate low enough to confidently call mutations from 
sequencing errors, but it cannot account for any discrepancies between the reference 
germline sequence and an individual’s germline sequence. Such mismatches would 
inflate SHM counts and lead to skewed repertoire analysis. We developed a simple yet 
effective technique for bioinformatically predicting novel germline alleles from antibody 
repertoire sequencing data and validating them experimentally. Each of the 8 individuals 
tested had at least 1 novel germline allele sequence, demonstrating the need to perform 
this type of correction. This approach should be used for any and all antibody repertoire 
sequencing analysis to instill confidence in SHM calling. 
We applied MIDCIRS to study the TFH TCR repertoire in HIV patients. Despite 
decimating the circulating CD4+ T cell population, HIV infection causes expansion of 
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functionally restricted TFH cells within secondary lymphoid tissues.  These functionally 
restricted TFH cells fail to induce a neutralizing antibody response to HIV. We showed 
that these expanded TFH cells were preferentially HIV-specific and showed signs of 
antigen-driven convergent evolution. It remains to be seen if interventions that restore 
polyfunctionality to these TFH cells can lead to a more robust antibody response. 
In future studies, the exquisite sensitivity and coverage of MIDCIRS could be 
useful not only for research applications but also for clinical diagnostics. B and T cells 
play a prominent role in many diseases. The enhanced ability to detect rare clones may 
prove useful for applications such as early diagnostic of autoimmune diseases. The ability 
to extract high quality sequencing data from minimal cell inputs may prove useful for 
TCR repertoire analysis of tumor infiltrating lymphocytes. Overall, IR-Seq is still in the 
infancy stage, and MIDCIRS adds another tool to the toolbox for researchers to expand 
our understanding of the immune system. 
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Appendix A – Chapter 2 Supplementary Information 
Primer name Sequence (5’-3’) 

























1st PCR reverse primer  
ILLUPE1adaptor_short ACACTCTTTCCCTACACGAC 
2nd PCR reverse primer  
ILLUPE1adaptor AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACAC
GAC 
2nd PCR forward 


















Table A.1:  Primers used for antibody sequence library generation.  
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Appendix B – Chapter 3 Supplementary Information 
Patient 








Inf1 Inf1-Pre3m 3m Yes I.S. Inf1-Acu9m 9m Yes 
Inf2 Inf2-Pre3m 3m Yes J.F. Inf2-Acu6m 6m Yes 
Inf3 Inf3-Pre5m 5m Yes I.S. Inf3-Acu11m 11m Yes 
Inf4 Inf4-Pre5m 5m Yes J.F. Inf4-Acu10m 10m Yes 
Inf5* Inf5-Pre5m 5m Yes J.F. Inf5-Acu10m 10m Yes 
Inf6 Inf6-Pre8m 8m Yes J.F. Inf6-Acu12m 12m Yes 
Inf7 Inf7-Pre11m 11m Yes Yes N.A. N.A. N.A. 
Inf8 Inf8-Pre11m 11m Yes Yes N.A. N.A. N.A. 
Inf9 Inf9-Pre11m 11m Yes Yes N.A. N.A. N.A. 
Inf10 Inf10-Pre11m 11m Yes Yes N.A. N.A. N.A. 
Inf11 Inf11-Pre11m 11m Yes Yes N.A. N.A. N.A. 
Tod1* Tod1-Pre17m 17m Yes Yes Tod1-Acu22m 22m Yes 
Tod2 Tod2-Pre19m 19m Yes Yes Tod2-Acu22m 22m Yes 
Tod3† Tod3-Pre28m 28m Yes Yes Tod3-Acu32m 32m Yes 
Tod4 Tod4-Pre29m 29m Yes Yes Tod4-Acu32m 32m Yes 
Tod5 Tod5-Pre31m 31m Yes J.F. Tod5-Acu32m 32m Yes 
Tod6 Tod6-Pre31m 31m Yes Yes Tod6-Acu38m 38m Yes 
Tod7† Tod7-Pre40m 40m Yes Yes Tod7-Acu42m 42m Yes 
Tod8 Tod8-Pre42m 42m Yes Yes Tod8-Acu46m 46m Yes 
Tod9 Tod9-Pre47m 47m Yes Yes Tod9-Acu50m 50m Yes 
Tod10 Tod10-Pre13m 13m Yes Yes N.A. N.A. N.A. 
Tod11 Tod11-Pre16m 16m Yes Yes N.A. N.A. N.A. 
Tod12 Tod12-Pre17m 17m Yes Yes N.A. N.A. N.A. 
Tod13 Tod13-Pre17m 17m Yes Yes N.A. N.A. N.A. 
Table B.1: Cohort and cell type availability. I.S. indicates insufficient PBMC for FACS 
sorting or analysis. J.F. indicates just flow cytometry analysis. N.A indicates 
samples were not available. * Same individual. † Same individual. 
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Inf1-Pre3m 3,000,000 3,246,180 2,989,252 92.1% 41,842 
Inf1-Acu9m 3,000,000 3,608,436 3,348,589 92.8% 32,800 
Inf2-Pre3m 3,000,000 3,176,623 2,987,587 94.0% 35,379 
Inf2-Acu6m 3,000,000 3,689,115 3,481,675 94.4% 29,523 
Inf3-Pre5m 4,150,000 3,242,619 3,070,458 94.7% 37,234 
Inf3-Acu11m 5,000,000 4,396,739 4,153,830 94.5% 42,634 
Inf4-Pre5m 5,000,000 3,048,762 2,810,018 92.2% 45,445 
Inf4-Acu10m 3,700,000 5,287,767 4,864,629 92.0% 29,694 
Inf5-Pre5m* 5,000,000 3,764,663 3,425,015 91.0% 54,516 
Inf5-Acu10m* 50,00,000 4,712,120 4,374,600 92.8% 41,774 
Inf6-Pre8m 5,000,000 3,588,177 3,456,165 96.3% 47,254 
Inf6-Acu12m 400,000 395,765 378,182 95.6% 03,447 
Tod1-Pre17m* 5,000,000 2,816,309 2,576,372 91.5% 53,551 
Tod1-Acu22m* 1,380,000 2,811,617 2,593,849 92.3% 12,514 
Tod2-Pre19m 5,000,000 4,842,338 4,673,875 96.5% 40,600 
Tod2-Acu22m 1,920,000 1,956,906 1,886,521 96.4% 15,285 
Tod3-Pre28m† 5,000,000 3,988,677 3,687,883 92.5% 35,567 
Tod3-Acu32m† 5,000,000 9,218,255 8,565,149 92.9% 47,144 
Tod4-Pre29m 5,000,000 2,924,629 2,851,964 97.5% 48,950 
Tod4-Acu32m 5,000,000 4,004,416 3,846,197 96.0% 40,628 
Tod5-Pre31m 5,000,000 5,338,867 5,126,888 96.0% 31,531 
Tod5-Acu32m 3,000,000 2,853,984 2,736,902 95.9% 26,955 
Tod6-Pre31m 5,000,000 4,356,975 4,198,929 96.4% 44,665 
Tod6-Acu38m 2,170,000 5,738,001 5,460,964 95.2% 22,270 
Tod7-Pre40m† 5,000,000 3,192,503 2,893,482 90.6% 34,901 
Tod7-Acu42m† 4,740,000 4,448,008 4,079,432 91.7% 34,185 
Tod8-Pre42m 5,000,000 2,120,127 2,058,164 97.1% 48,939 
Tod8-Acu46m 2,100,000 2,060,234 1,986,239 96.4% 17,039 
Tod9-Pre47m 3,000,000 3,035,618 2,682,991 88.4% 20,094 
Tod9-Acu50m 3,000,000 4,678,879 3,912,981 83.6% 18,447 
Table B.2: Sequencing reads statistics of paired PBMCs from the malaria cohort. 
aNumber of PBMCs differs because of the age dependent blood draw 
volume and cell recovery. * Same individual. † Same individual. 
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Figure B.1: Rarefaction analysis of paired PBMC malaria cohort sequencing libraries. 
(a) Pre-malaria PBMC rarefaction curves (N=15). (b) Acute malaria PBMC 
rarefaction curves (N=15). Raw reads were subsampled to varying depths, 
and MIDCIRS was used to determine the number of unique RNA 
molecules. All single-read sequences that occurred before subsampling were 
discarded. Single-read sequences that occurred as a results of subsampling 
were included as unique RNA molecules. The number of unique RNA 
molecules discovered saturated for all samples, indicating adequate 
sequencing depth.   
Sample 
Percentage of Unique RNA sequences 

































Table B.3: Percentage of unique RNA sequences assigned to novel alleles for each 
sample. Novel alleles detected by TIgGER and our method were combined. 
































Number of naive B 
cells 
Average number of 
mutations 
Inf1-Acu9m 10000 0.31 
Inf2-Pre3m 10000 0.20 
Inf3-Pre5m 10000 0.29 
Inf4-Pre5m 10000 0.27 
Inf5-Pre5m* 10000 0.40 
Tod1-Pre17m* 10000 0.79 
Tod2-Pre19m 10000 0.57 
Tod3-Pre28m† 10000 0.53 
Tod4-Pre29m 100000 1.07 
Tod7-Pre40m† 10000 0.45 
Tod8-Pre42m 100000 1.20 





Figure B.2: Correlation between average number of mutations and age for initial, paired 
pre- and acute malaria samples. Initial samples (N=15) suggested a step-
wise increase in SHM load around 12 months which prompted us to divide 
our cohort into two age groups and delve further into the antibody repertoire 
properties. We since added 9 pre-malaria samples around the transition, 11 




Figure B.3:  Comparison between pre-malaria plasmablast percentage of total B cells and 
average number of mutations. (a) Plasmablast percentages of total B cells 
compared with age. (b-d) Plasmablast percentages of total B cells compared 
with average number of mutations of IgM (b), IgG (c), and IgA (d) 
sequences from bulk PBMCs in pre-malaria samples from infants (N=9) and 
toddlers (N=13). ρ and P values determined by Spearman’s rank correlation 














IgM 0.54 0.11 4.98 0.18 0.04 5.15 
3.00 ± 1.12 5.54 ± 0.25 
IgG 1.54 0.70 2.21 1.36 0.24 5.67 
IgA 1.48 0.65 2.28 1.29 0.22 5.75 
Acute 
IgM 1.36 0.34 4.05 0.58 0.11 5.52 
IgG 1.88 0.85 2.22 1.62 0.30 5.35 
IgA 2.03 0.90 2.25 1.75 0.30 5.79 
Toddler 
Pre 
IgM 1.12 0.35 3.20 0.58 0.11 5.54 
2.41 ± 0.45 5.34 ± 0.25 
IgG 3.42 1.57 2.17 2.73 0.54 5.05 
IgA 3.88 1.82 2.14 3.15 0.58 5.41 
Acute 
IgM 2.16 0.79 2.73 1.33 0.24 5.44 
IgG 4.28 2.02 2.11 3.39 0.68 5.02 
IgA 4.33 2.04 2.12 3.55 0.64 5.59 
Table B.5: Replacement and silent mutations and their ratios for PBMCs in infants and 
toddlers. Nucleotide mutations resulting in amino acid substitutions 
(Replacement, R) or no amino acid substitutions (silent, S) in the framework 
region (FWR2 and 3) and complementary determining regions (CDR1 and 
2) of infants (N=6) and toddlers (N=9), weighted by unique RNA 
molecules.  CDR3 and FWR4 were not included in this analysis due to the 
difficulty determining the germline sequence. FWR1 for all sequences was 
also omitted because it was not covered entirely by some of the primers. 






Figure B.4: Lineage structure visualization.  Lineage distribution structures for pre-
malaria and acute malaria samples for all individuals with corresponding 
pre-malaria and acute malaria PBMC samples.  A 24 year old adult malaria 
patient was also included. Lineages composed of only a single unique RNA 
molecule were excluded. Clonal lineages shown in Figure 3.10 are densely 
packed here. Therefore, it is not intended to show intra-lineage structure for 
all individual lineages in each panel; rather, each panel provides an 
overview of all lineages for one individual at one timepoint. The darker the 
cluster in each oval-shaped global lineage map, the more densely packed 




Figure B.5: Comparison between different thresholds for lineage formation. 90% (blue) 
and 95% (pink) nucleotide similarities of the CDR3 region were used as the 
threshold to generate lineages. The distribution of the size vs diversity of 
lineages and the linear regressions (blue and pink dashed lines) of the 
lineage distributions generated by the two thresholds were compared. The 
area of the circle corresponds to the average SHM within the lineage. Black 




Figure B.6: Adult B cell lineage diversification. Size and diversity of B cell lineages 
between pre-malaria (blue) and acute malaria (pink) samples for a 24 year 
old adult malaria patient. Area of the circles corresponds to the average 
number of mutations within that lineage.  Dashed lines represent the linear 
fit for pre- (blue) and acute (pink) lineages; black dotted line depicts y=x 




Figure B.7: Pre-malaria lineage diversification between infants and toddlers. Pre-malaria 
lineage size/diversity linear regression slopes (Figure 3.9, blue dashed lines) 
were compared between infants (black) and toddlers (red). N.S. indicates not 




Patient Shared lineages 
Unique memory 
B cell Sequences 
Containing pre-malaria 
memory B cells 
Inf1 29 N.A. N.A. 
Inf2 131 N.A. N.A. 
Inf3 215 N.A. N.A. 
Inf4 142 N.A. N.A. 
Inf5* 214 N.A. N.A. 
Inf6 83 N.A. N.A. 
Tod1* 308 3,423 149 
Tod2 385 7,856 145 
Tod3† 1230 6,023 926 
Tod4 1194 5,073 209 
Tod5 260 N.A. N.A. 
Tod6 346 6,363 111 
Tod7† 472 4,771 161 
Tod8 581 2,399 98 
Tod9 414 2,534 135 
Table B.6: Pre-malaria and acute malaria shared lineage count. The number of lineages 
containing sequences from both the pre-malaria and acute malaria 
timepoints. For malaria-experienced individuals with 10,000 FACS sorted 
pre-malaria memory B cells available, the number of unique memory B cell 
sequences and two-timepoint-shared lineages that contain sequences from 
the sorted memory B cells from the pre-malaria timepoint. N.A. indicates 





Figure B.8: Flow cytometry B cell gating and atypical memory percentage. B cells were 
first gated by scatter, then live, dump (CD4, CD8, CD14, CD56) negative, 
and then CD19+. Conventional memory B cells (CD20+CD27+), 
plasmablasts (CD27brightCD38bright), and naïve B cells (CD20+CD27-
CD38low) were gated for further analysis. Atypical memory B cells 
(CD20+CD27-CD38lowIgD-) make up a minor portion of the naïve-like B 




Figure B.9: Pre-malaria memory B cells’ acute progeny RNA abundance. Shared 
lineages containing sequences from pre-malaria memory B cells and acute 
malaria PBMCs were formed as in Figure 3.13 and Figure 3.15. Acute 
sequences from these lineages were classified as direct progeny (pink, 
corresponding to pink box in Figure 3.14) if they can be traced directly 
back to a pre-malaria memory B cell sequence or indirect progeny (green, 
corresponding to acute sequences in the same lineages as the dark blue slice 
in Figure 3.14) if they cannot (i.e. they stem from a separate branch in the 
lineage tree). The RNA abundance distribution for these sequences were 
split by isotype and compared to the bulk acute PBMCs (black) from the 
same individuals (N=8 toddlers, Tod5 was not included because there were 
insufficient cells for FACS sorting). Vertical dashed line indicates 10 RNA 
molecule cutoff, with the percentage of unique RNA molecules larger than 















Germline a g t g g t g g t t a c t a c t g g a g c t g g a t c c g c c a g c a c c c a g g g a a g g g c c t g g a g t g g a t t g g g t a c a t c t a t t a c a g t g g
0 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7 Inf-Acu11m, IgG . . . . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . . . . . .
8 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . .
9 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . . . . . . . . . . . . c . . .
11 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Germline g a g c a c c t a c t a c a a c c c g t c c c t c a a g a g t c g a g t t a c c a t a t c a g t a g a c a c g t c t a a g a a c c a g t t c t c c c t g a a g c
0 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a .
3 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . .
4 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . .
7 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9 Inf-Acu11m, IgA . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . c . . . t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 Inf-Acu11m, IgG . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Germline t g a g c t c t g t g a c t g c c g c g g a c a c g g c c g t g t a t t a c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 Inf-Acu11m, IgA . . . . . . . . . . . . g . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . . . . . . . . . . . . . t . . . . . .
Germline
0 Inf-Acu11m, IgG g g c c a g g g a a c c c t g g t c a c c g t c t c c t c a
1 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9 Inf-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 Inf-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






















Germline t g g g t g c g a c a g g c c c c t g g a c a a g g g c t t g a g t g g a t g g g a t g g a t c a g c g c t t a c a a t g g t a a c a c a a a c t a t g c a c a
0 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . g . . . g . . . . . . a . . . . . . . . . . . . . .
1 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . g . a . . . . g . . . g . . . . . . a . . . . . . . . . . . . . .
2 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . g . . . c . . . . . . a . . . . . . . . . . . . . .
3 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . g . . . g . . . . . . a . . . . . . . . . . . . . .
4 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . g . . . g . a c . . . a . . . . . . . . . . . . . .
5 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . g . . . g . a . . . . a . . . . c . . . . . . . . .
6 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . g . . t . . a c . . . a . . . . . . . . . . . . . .
7 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . a . a . . a . . . g . . . . . . . . t . . . g . . . . . . . .
Germline g a a g c t c c a g g g c a g a g t c a c c a t g a c c a c a g a c a c a t c c a c g a g c a c a g c c t a c a t g g a g c t g a g g a g c c t g a g a t c t g
0 Inf3-Acu11m, IgA . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . . . . . . .
1 Inf3-Acu11m, IgG . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . . . . . . .
2 Inf3-Acu11m, IgG . . . a . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . . . . . . .
3 Inf3-Acu11m, IgA . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . t . t . . . . . . t . . a . . . . . . . . . . . . . . . . . . . a . .
4 Inf3-Acu11m, IgG . . . a . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . g . . . . . . . . . . . . . . t . . . . . . t . . . . . . . . . . . . . . . . . .
5 Inf3-Acu11m, IgA . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . t . . . . . a a . . . . . . a . . . . . . . . . . .
6 Inf3-Acu11m, IgG . . . a . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . g . . . . . . . . . . . . . . t . . . . . . t . . . . . . . . . . . . . . . . . .
7 Inf3-Acu11m, IgA . . . a . . . . . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . c . . . . .
Germline a c g a c a c g g c c g t g t a t t a c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . . . . . . . . . . . . . .
2 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Germline g g c c a g g g a a c c c t g g t c a c c g t c t c c t c a
0 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Inf3-Acu11m, IgG . . . . g . . . . . . . . . . . . . . . . . . . . . . . . .
3 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Inf3-Acu11m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Inf3-Acu11m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





Figure B.10 Sequence alignment for illustrated lineages. The CDR3 region has been 
highlighted in yellow.  The top row displays the IMGT germline allele 
sequence, and dashes indicate where the sequences are identical to the 
germline. (a) Corresponds to the lineage in Figure 3.10a, (b) corresponds to 
the lineage in Figure 3.10b and (c) corresponds to the lineage in Figure 
3.13. 
  
Germline c a c t g g g t c c g c c a g g c t t c c g g g a a a g g g c t g g a g t g g g t t g g c c g t a t t a g a a g c a a a g c t a a c a g t t a c g c g a c a g c
0 Tod4-Pre29m, IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
1 Tod4-Acu32m, IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
2 Tod4-Acu32m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
3 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
4 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
5 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
6 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
7 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . a . . . . . . a . . . . . . . . . . . .
8 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
9 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . a . . . . . . . . . . . .
Germline a t a t g c t g c g t c g g t g a a a g g c a g g t t c a c c a t c t c c a g a g a t g a t t c a a a g a a c a c g g c g t a t c t g c a a a t g a a c a g c c
0 Tod4-Pre29m, IgM . . t c . . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . g . . . . . .
1 Tod4-Acu32m, IgM . . t c . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . .
2 Tod4-Acu32m, IgG . . t c . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . .
3 Tod4-Acu32m, IgA . . t c . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . t . . . . . . . . . . . . . . . . .
4 Tod4-Acu32m, IgA . . t c . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . t . . . . . . . . . . . . . . . . .
5 Tod4-Acu32m, IgA . . t c . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . t . . . . . . . . . . . . . . . . .
6 Tod4-Acu32m, IgA . . t c . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . t . . . . . . . . . . . . . . . . .
7 Tod4-Acu32m, IgA . . t c . . . . . . . . . . . . c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . .
8 Tod4-Acu32m, IgA . . t c . . . . . . . . . . . a c . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . .
9 Tod4-Acu32m, IgA . . t c . . . . . . . . . . . a c . . . . . . . . . . . . t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . c . . . . . . . . . . . . . . . . . .
Germline t g a a a a c c g a g g a c a c g g c c g t g t a t t a c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0 Tod4-Pre29m, IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 Tod4-Acu32m, IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Tod4-Acu32m, IgG . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . .
3 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . a . . . . . . . t . . . g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . .
6 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . .
7 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . a . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . .
8 Tod4-Acu32m, IgA . . . . . . . . . . a . . . . . . . . . a . c . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . .
9 Tod4-Acu32m, IgA . . . . . . . . . . a . . . . . . . . . a . c . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . . g . . . . . . . . . . . . . . . . . . . . . . .
Germline g g c c a g g g a a c c c t g g t c a c c g t c t c c t c a
0 Tod4-Pre29m, IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 Tod4-Acu32m, IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Tod4-Acu32m, IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7 Tod4-Acu32m, IgA . . . . . . . . . . . . . . a . . . . . . . . . . . . . . .
8 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9 Tod4-Acu32m, IgA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c 
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Appendix C – Chapter 4 Supplementary Information 








































































Table C.1: gDNA validation primer list. Sequences in red indicate common partial 
Illumina adaptors; NNNNNN in blue indicates fixed library indexes used to 
pool multiple libraries into a single run. 
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Appendix D – Chapter 5 Supplementary Information 
113 CD57 HCD57 Biolegend 
141 CD3 UCTH1 BD 
142 CD5 UCHT2 Biolegend 
143 CD8 SK1 Biolegend 
144 CD4  SK3 Biolegend 
145 CD19 HIB19 Biolegend 
146 IgD IA6-2 Biolegend 
147 IFNg 4S.B3 eBioscience 
148 CCR6 G034E3 Biolegend 
149 CD14 M5E2 Biolegend 
150 CD69 FN50 Biolegend 
151 Granzyme A CB9 Biolegend 
152 TNFa MAb11 Biolegend 
153 CD45RO UCHL1 Biolegend 
154 CD27 LG.7F9 eBioscience 
155 TCRab T10B9.1A-31 BD 
156 CCR5 J418F1 Biolegend 
157 Ki67 B56 BD 
158 BLYS 1D6 Biolegend 
159 BCL6 K112-91 BD 
160 IL4 8D4-8 BD 
161 CD25 M-A251 BD 
162 Eomes wd1928 eBioscience 
163 ICOS c398-4A Biolegend 
164 IL5  TRFK5 Biolegend 
165 Foxp3 PCH101 eBioscience 
166 CD95 DX2 Biolegend 
167 CD45RA HI100 eBioscience 
168 CCR7 G043H7 Biolegend 
169 CXCR5 RF8B2 BD 
170 Tbet 4B10 Biolegend 
171 PD-1 EH12.2H7 Biolegend 
172 IL-21  3A3-N2 Biolegend 
173 IL2 MQ1-17H12 eBioscience 
174 CD24 ML5 Biolegend 
175 CXCR3 G025H7 Biolegend 
176 CD38 HIT2 Biolegend 
Table D.1: CyTOF antibody staining panel. Table produced by L.F.S. 
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Table D.2: Clinical characteristics and demographic information of LN samples. Table 
produced by L.F.S. 
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  Naïve Memory GC TFH 
Subject Cells TCR transcripts Cells TCR transcripts Cells TCR transcripts 
H2 10,000 14,420 10,000 6,315 15,000 33,904 
H3 10,000 6,750 10,000 8,945 10,000 7,954 
H8 10,000 13,225 10,000 5,992 10,000 26,374 
H10 10,000 4,314 10,000 9,033 1,464 2,498 
H14 10,000 5,822 10,000 6,254 10,000 11,197 
H17 10,000 18,376 10,000 6,533 10,995 37,129 
H21 10,000 10,404 10,000 7,503 10,227 23,673 
H24 10,000 5,488 10,000 2,821 10,000 9,220 




Figure D.1: Identification of GC TFH cells from LN samples.  Representative gating to 
identify GC TFH cells using data from an HIV
+ sample.  Cryopreserved LN 
cells were stimulated with PMA and ionomycin in the presence of Brefeldin 
A and monensin, stained with a panel of 37 surface and intracellular 
markers, and analyzed by mass cytometry.  After exclusion of dead cells 
(Cisplatin+), doublets (by event length), beads (Cd140+), and elimination of 
background signal in an empty gate (La139), lineage gating was performed 
to identify CD3+CD4+TCRαβ+ T cells.  GC TFH cells were identified as the 
subset of CXCR5+ CD45RO+ CD4+ T cells that express CD57 and PD-1. 




Figure D.2: Phenotypic group distribution is different between HC, IBD, and HIV 
samples. Frequency of g1 (A), g2 (B), g3 (C), or g4 (D) in HC, IBD, and 
HIV samples.  Statistical significance was analyzed using two-tailed 
Student’s t-test for pair-wise comparison. Significance level is set at p < 
0.0167 to correct for three-way comparison.  * P < 0.0167, ** P < 0.00167, 




Figure D.3: Identification of B cell subsets.  (A) Plots showing gating strategy to identify 
naïve B cells (IgD+CD27-, 1).  (B) Non-naïve subsets are divided based on 
IgD and CD38 expression into unswitched memory B cells (IgD+, 2), 
switched memory B cells (IgD-CD38-, 3), GC B cells (IgD-CD38+, 4), and 
plasma cells (IgD-CD38high, 5).  (C) Bar-graph showing the distribution of B 
cell subsets in HIV+ and HC LNs.  Differences between HIV and HC were 





Figure D.4: IL-21 poly-functionality is associated with distinct B cell phenotypes. (A-D) 
Correlation between plasma cells or switched B cells with IL-21 only GC 
TFH cells (A,B).   An inverse trend is observed for IL21+2 GC TFH cells 
(C,D).  (E-H)  Correlation between IL-21 only and IL21+2 
CXCR5+CD45RO+CD4+ T cells with plasma cells and switched B cells as 
in A-D. Spearman rank correlation and least squares fit regression were 




Figure D.5: Frequency of IL-21-producing subsets in TFH cells in HIV and HC samples.  
(A,B) Bar graph shows all cytokine-positive IL-21-producing subsets in 
combination with other effector molecules (IL-2, IFN-γ, TNF-α, IL-4, or 
granzyme A).  These subsets were generated by applying Boolean 
combination gating on IL-21+ GC TFH (A) or CXCR5
+ memory CD4+ T 
cells (B). Statistical significance was analyzed using Student’s t-test for 
pair-wise comparison. Multiple comparisons are corrected using Holm-





Figure D.6: Frequency of IL-21-producing subsets in TFH cells in HIV and IBD samples.  
(A-B) Bar graph shows all cytokine positive IL-21 producing subsets in 
combination with other effector molecules (IL-2, IFN-γ, TNF-α, IL-4, or 
granzyme A).  These subsets were generated as in Figure D.5. Statistical 
significance was analyzed using Student’s t-test for pair-wise comparison. 
Multiple comparisons are corrected using Holm-Sidak method, with 






Figure D.7: Antigen-driven clonal selection signature in GC TFH cells of HIV
+ LNs. 
Coding degeneracy level (number of unique TCR nucleotide (nt) sequences 
encoding a common CDR3 amino acid (aa) sequence) of each CDR3 aa 
sequence is plotted against their frequency (measured as % of total TCR 
transcript) in naïve, memory, and GC TFH cells. Each dot is a unique CDR3 
aa sequence. Red dashed lines indicate cutoffs for degenerate (2 or more nt 
sequences coding for the same aa sequence, horizontal) and expanded (0.1% 
or more of TCR transcripts, vertical) clones. Each panel is broken into 4 
quadrants: Q1: degenerate-abundant clones; Q2: degenerate-rare clones; Q3: 






Figure D.8: HA-specific CD4+ T cells within HIV+ LNs lack clonal expansion and 
selection signatures. (A) HA-specific TCR clones overlap with HIV+ LN 
CD4+ T cell populations. Each thin slice of the arc represents a unique TCR 
sequence, ordered by the clone size (darker green for larger clones, inner 
circle). Grey curves indicate HA-specific TCR clones (nt sequences) found 
in naïve (black, outer circle), memory (blue, outer circle), and GC TFH 
(orange, outer circle) populations. (B) Number of HA-specific TCR clones 
observed in naïve (black), memory (blue), and GC TFH (orange) populations. 
Grey lines connect samples from the same patient. Bars indicate means. (C) 
Mean clone size of HA-specific clones (magenta) and clones of unknown 
specificity (black) from naïve, memory, and GC TFH populations. (D) 
Degeneracy, or the number of distinct nt sequences per CDR3 aa sequence, 
of HA-specific clones (magenta) and clones of unknown specificity (black) 
from naïve, memory, and GC TFH populations. Data from all 6 subjects were 




Table D.4: TCRβ Sequencing Primers. Red Ns indicate 12N random molecular identified 
(MID). Blue Ns indicate fixed Illumina i7 indexes used for pooling multiple 
libraries for a single run. 
 
Primer Target Sequence PCR Step
TCRb Constant ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT NNN NNN NNN NNN GAC CTC GGG TGG GAA CAC Reverse Transcription
TRBV1 GAC GTG TGC TCT TCC GAT CTC TGA CAG CTC TCG CTT ATA CCT TCA
TRBV2 GAC GTG TGC TCT TCC GAT CTG CCT GAT GGA TCA AAT TTC ACT CTG
TRBV3 GAC GTG TGC TCT TCC GAT CTA ATG AAA CAG TTC CAA ATC GMT TCT
TRBV4 GAC GTG TGC TCT TCC GAT CTC CAA GTC GCT TCT CAC CTG AAT
TRBV5-1 GAC GTG TGC TCT TCC GAT CTC GCC AGT TCT CTA ACT CTC GCT CT
TRBV5-2 GAC GTG TGC TCT TCC GAT CTT TAC TGA GTC AAA CAC GGA GCT AGG
TRBV5-3 GAC GTG TGC TCT TCC GAT CTC TCT GAG ATG AAT GTG AGT GCC TTG
TRBV5-4/5/6/7/8 GAC GTG TGC TCT TCC GAT CTC TGA GCT GAA TGT GAA CGC CTT G
TRBV6-1 GAC GTG TGC TCT TCC GAT CTT CTC CAG ATT AAA CAA ACG GGA GTT
TRBV6-2/3 GAC GTG TGC TCT TCC GAT CTC TGA TGG CTA CAA TGT CTC CAG ATT
TRBV6-4 GAC GTG TGC TCT TCC GAT CTA GTG TCT CCA GAG CAA ACA CAG ATG
TRBV6-5/6/7 GAC GTG TGC TCT TCC GAT CTG TCT CCA GAT CAA MCA CAG AGG ATT
TRBV6-8/9 GAC GTG TGC TCT TCC GAT CTA AAC ACA GAG GAT TTC CCR CTC AG
TRBV7-1 GAC GTG TGC TCT TCC GAT CTG TCT GAG GGA TCC ATC TCC ACT C
TRBV7-2 GAC GTG TGC TCT TCC GAT CTT CGC TTC TCT GCA GAG AGG ACT GG
TRBV7-3 GAC GTG TGC TCT TCC GAT CTC TGA GGG ATC CGT CTC TAC TCT GAA
TRBV7-4/8 GAC GTG TGC TCT TCC GAT CTC TGA GRG ATC CGT CTC CAC TCT G
TRBV7-5 GAC GTG TGC TCT TCC GAT CTG GTC TGA GGA TCT TTC TCC ACC T
TRBV7-6/7 GAC GTG TGC TCT TCC GAT CTG AGG GAT CCA TCT CCA CTC TGA C
TRBV7-9 GAC GTG TGC TCT TCC GAT CTC TGC AGA GAG GCC TAA GGG ATC T
TRBV8-1 GAC GTG TGC TCT TCC GAT CTA AGC TCA AGC ATT TTC CCT CAA C
TRBV8-2 GAC GTG TGC TCT TCC GAT CTA TGT CAC AGA GGG GTA CTG TGT TTC
TRBV9 GAC GTG TGC TCT TCC GAT CTA CAG TTC CCT GAC TTG CAC TCT G
TRBV10-1/3 GAC GTG TGC TCT TCC GAT CTA CAA AGG AGA AGT CTC AGA TGG CTA
TRBV10-2 GAC GTG TGC TCT TCC GAT CTT GTC TCC AGA TCC AAG ACA GAG AA
TRBV11 GAC GTG TGC TCT TCC GAT CTC TGC AGA GAG GCT CAA AGG AGT AG
TRBV12-1/2 GAC GTG TGC TCT TCC GAT CTA TCA TTC TCY ACT CTG AGG ATC CAR
TRVB12-3/4/5 GAC GTG TGC TCT TCC GAT CTA CTC TGA RGA TCC AGC CCT CAG AAC
TRBV13 GAC GTG TGC TCT TCC GAT CTC AGC TCA ACA GTT CAG TGA CTA TCA T
TRBV14 GAC GTG TGC TCT TCC GAT CTG AAA GGA CTG GAG GGA CGT ATT CTA
TRBV15 GAC GTG TGC TCT TCC GAT CTG CCG AAC ACT TCT TTC TGC TTT CT
TRBV16 GAC GTG TGC TCT TCC GAT CTA TTT TCA GCT AAG TGC CTC CCA AAT
TRBV17 GAC GTG TGC TCT TCC GAT CTC ACA GCT GAA AGA CCT AAC GGA AC
TRBV18 GAC GTG TGC TCT TCC GAT CTA TTT TCT GCT GAA TTT CCC AAA GAG
TRBV19 GAC GTG TGC TCT TCC GAT CTG TCT CTC GGG AGA AGA AGG AAT C
TRBV20-1 GAC GTG TGC TCT TCC GAT CTG ACA AGT TTC TCA TCA ACC ATG CAA
TRBV21-1 GAC GTG TGC TCT TCC GAT CTC AAT GCT CCA AAA ACT CAT CCT GT
TRBV22-1 GAC GTG TGC TCT TCC GAT CTA GGA GAA GGG GCT ATT TCT TCT CAG
TRBV23-1 GAC GTG TGC TCT TCC GAT CTA TTC TCA TCT CAA TGC CCC AAG AAC
TRBV24-1 GAC GTG TGC TCT TCC GAT CTG ACA GGC ACA GGC TAA ATT CTC C
TRBV25-1 GAC GTG TGC TCT TCC GAT CTA GTC TCC AGA ATA AGG ACG GAG CAT
TRBV26 GAC GTG TGC TCT TCC GAT CTC TCT GAG GGG TAT CAT GTT TCT TGA
TRBV27 GAC GTG TGC TCT TCC GAT CTC AAA GTC TCT CGA AAA GAG AAG AGG A
TRBV28 GAC GTG TGC TCT TCC GAT CTA AGA AGG AGC GCT TCT CCC TGA TT
TRBV29-1 GAC GTG TGC TCT TCC GAT CTC GCC CAA ACC TAA CAT TCT CAA
TRBV30 GAC GTG TGC TCT TCC GAT CTC CAG AAT CTC TCA GCC TCC AGA C
ILLUPE1adaptor_short ACA CTC TTT CCC TAC ACG AC 1st PCR, reverse
ILLUPE2adaptor_full CAA GCA GAA GAC GGC ATA CGA GAT AA NNN NNN GTG ACT GGA GTT CAG ACG TG 2nd PCR, forward
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